

# Pharmacotherapy for Adults With Alcohol Use Disorder

JAMA - Journal of the American Medical Association

311, 1889

DOI: [10.1001/jama.2014.3628](https://doi.org/10.1001/jama.2014.3628)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Chronic AUD patients treated more poorly. <i>Gastrointestinal Nursing</i> , 2014, 12, 11-12.	0.0	0
2	Research roundup: June 2014. <i>NursePrescribing</i> , 2014, 12, 270-271.	0.1	0
3	Genetic markers associated with abstinence length in alcohol-dependent subjects treated with acamprosate. <i>Translational Psychiatry</i> , 2014, 4, e453-e453.	2.4	52
4	Lost in translation? Moving contingency management and cognitive behavioral therapy into clinical practice. <i>Annals of the New York Academy of Sciences</i> , 2014, 1327, 94-111.	1.8	49
6	Medications for Alcohol Use Disorders. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 1350.	3.8	1
7	Medications for Alcohol Use Disorders. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 1349.	3.8	4
8	If pharmacotherapies for alcohol use disorders are effective, why are they underutilised?. <i>Evidence-Based Medicine</i> , 2014, 19, 230-231.	0.6	6
9	Genetic polymorphisms and response to medications for alcohol use disorders: a systematic review and meta-analysis. <i>Pharmacogenomics</i> , 2014, 15, 1687-1700.	0.6	24
10	Bringing Patient-Centered Care to Patients With Alcohol Use Disorders. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1861.	3.8	80
11	Medications for Alcohol Use Disorders. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 1350.	3.8	1
13	Alcohol and drug use among adolescents: an educational overview. <i>International Journal of Adolescent Medicine and Health</i> , 2015, 27, 207-212.	0.6	20
14	Leptin levels are reduced by intravenous ghrelin administration and correlated with cue-induced alcohol craving. <i>Translational Psychiatry</i> , 2015, 5, e646-e646.	2.4	36
15	Combining seeking safety with sertraline for PTSD and alcohol use disorders: A randomized controlled trial.. <i>Journal of Consulting and Clinical Psychology</i> , 2015, 83, 359-369.	1.6	69
18	The Need for Treatment Responsive Translational Biomarkers in Alcoholism Research. <i>Current Topics in Behavioral Neurosciences</i> , 2015, 28, 151-171.	0.8	35
19	Brief Intervention Decreases Drinking Frequency in HIV-Infected, Heavy Drinking Women. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 70, 137-145.	0.9	72
20	Specialty substance use disorder services following brief alcohol intervention: a meta-analysis of randomized controlled trials. <i>Addiction</i> , 2015, 110, 1404-1415.	1.7	124
21	Guidelines for the Reporting of Treatment Trials for Alcohol Use Disorders. <i>Alcoholism: Clinical and Experimental Research</i> , 2015, 39, 1571-1581.	1.4	28
22	Recommendations for the Design and Analysis of Treatment Trials for Alcohol Use Disorders. <i>Alcoholism: Clinical and Experimental Research</i> , 2015, 39, 1557-1570.	1.4	61

#	ARTICLE	IF	CITATIONS
23	Alcohol liver disease: A review of current therapeutic approaches to achieve long-term abstinence. World Journal of Gastroenterology, 2015, 21, 8516.	1.4	10
24	Use of Pharmacotherapies in the Treatment of Alcohol Use Disorders and Opioid Dependence in Primary Care. BioMed Research International, 2015, 2015, 1-11.	0.9	17
25	Advances in alcoholic liver disease: An update on alcoholic hepatitis. World Journal of Gastroenterology, 2015, 21, 11893.	1.4	23
26	Adoption of Injectable Naltrexone in U.S. Substance Use Disorder Treatment Programs. Journal of Studies on Alcohol and Drugs, 2015, 76, 143-151.	0.6	48
27	Nalmefene and alcohol dependence: a new approach or the same old unacceptable marketing?. Substance Abuse and Rehabilitation, 2015, 6, 75.	1.6	6
28	Update in Outpatient General Internal Medicine: Practice-changing Evidence Published in 2014. American Journal of Medicine, 2015, 128, 1065-1069.	0.6	1
30	Safety and tolerability of as-needed nalmefene in the treatment of alcohol dependence: results from the Phase III clinical programme. Expert Opinion on Drug Safety, 2015, 14, 495-504.	1.0	18
31	Assessment and management of alcohol use disorders. BMJ, The, 2015, 350, h715-h715.	3.0	19
32	An Inpatient Treatment and Discharge Planning Protocol for Alcohol Dependence: Efficacy in Reducing 30-Day Readmissions and Emergency Department Visits. Journal of General Internal Medicine, 2015, 30, 365-370.	1.3	82
33	Acamprosate: A Review of Its Use in Alcohol Dependence. Drugs, 2015, 75, 1255-1268.	4.9	52
34	Comprehensive Care of Patients with Chronic Liver Disease. Medical Clinics of North America, 2015, 99, 913-933.	1.1	12
35	The Prescription of Addiction Medications After Implementation of Chronic Care Management for Substance Dependence in Primary Care. Journal of Substance Abuse Treatment, 2015, 52, 17-23.	1.5	9
36	Has evidence-based medicine left quackery behind?. Internal and Emergency Medicine, 2015, 10, 631-634.	1.0	18
37	In Treating Alcohol Use Disorders, Why Not Use Evidence-Based Treatment?. American Journal of Psychiatry, 2015, 172, 305-306.	4.0	7
38	Naltrexone vs Placebo for the Treatment of Alcohol Dependence. JAMA Psychiatry, 2015, 72, 430.	6.0	101
39	Pharmacotherapy for Alcohol Use Disorder. Harvard Review of Psychiatry, 2015, 23, 122-133.	0.9	74
40	A systemic failure to address at-risk drinking and alcohol use disorders: the Canadian story. Cmaj, 2015, 187, 479-480.	0.9	3
41	Identifying Medication Targets for Psychostimulant Addiction: Unraveling the Dopamine D3 Receptor Hypothesis. Journal of Medicinal Chemistry, 2015, 58, 5361-5380.	2.9	86

#	ARTICLE	IF	CITATIONS
44	Extended Release Naltrexone for Alcohol Use Disorders: Quasi-Experimental Effects on Mortality and Subsequent Detoxification Episodes. <i>Alcoholism: Clinical and Experimental Research</i> , 2015, 39, 79-83.	1.4	5
45	Effects of Idazoxan on Alcohol Pharmacokinetics and Intoxication: A Preliminary Human Laboratory Study. <i>Alcoholism: Clinical and Experimental Research</i> , 2015, 39, 594-602.	1.4	12
46	The Importance of Animals in Advancing Research on Alcohol Use Disorders. <i>Alcoholism: Clinical and Experimental Research</i> , 2015, 39, 575-578.	1.4	2
47	The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence, Europe versus the rest of the world: a meta-analysis. <i>Addiction</i> , 2015, 110, 920-930.	1.7	99
48	Effects of Varenicline on Neural Correlates of Alcohol Salience in Heavy Drinkers. <i>International Journal of Neuropsychopharmacology</i> , 2015, 18, pyv068.	1.0	24
49	The Impact of Alcohol Use and Related Disorders on the HIV Continuum of Care: a Systematic Review. <i>Current HIV/AIDS Reports</i> , 2015, 12, 421-436.	1.1	155
50	Elevated baseline serum glutamate as a pharmacometabolomic biomarker for acamprosate treatment outcome in alcohol-dependent subjects. <i>Translational Psychiatry</i> , 2015, 5, e621-e621.	2.4	39
51	Comparative utilization of pharmacotherapy for alcohol use disorder and other psychiatric disorders among U.S. Veterans Health Administration patients with dual diagnoses. <i>Journal of Psychiatric Research</i> , 2015, 69, 150-157.	1.5	46
52	New perspectives for the treatment of alcoholism. <i>Medicina Clínica (English Edition)</i> , 2015, 144, 24-25.	0.1	0
54	What the alcohol doctor ordered from the neuroscientist. <i>Progress in Brain Research</i> , 2016, 224, 401-418.	0.9	20
56	Specialist treatment of drinking problems. , 0, , 190-214.		0
57	High-Dose Naltrexone Treatment and Gender in Alcohol Dependence. <i>Clinical Neuropharmacology</i> , 2016, 39, 165-168.	0.2	8
58	Specifying and Pilot Testing Quality Measures for the American Society of Addiction Medicine's Standards of Care. <i>Journal of Addiction Medicine</i> , 2016, 10, 148-155.	1.4	25
59	Pharmacotherapy for Substance Use Disorders in Youths. <i>Journal of Child and Adolescent Substance Abuse</i> , 2016, 25, 292-316.	0.5	13
60	The Effect of Varenicline on the Neural Processing of Fearful Faces and the Subjective Effects of Alcohol in Heavy Drinkers. <i>Alcoholism: Clinical and Experimental Research</i> , 2016, 40, 979-987.	1.4	19
61	A Point-by-Point Response to Brailon. <i>CNS Neuroscience and Therapeutics</i> , 2016, 22, 537-538.	1.9	0
62	Craving Mediates Stress in Predicting Lapse During Alcohol Dependence Treatment. <i>Alcoholism: Clinical and Experimental Research</i> , 2016, 40, 1058-1064.	1.4	27
63	Pharmacotherapy for Alcohol Dependence: The 2015 Recommendations of the French Alcohol Society, Issued in Partnership with the European Federation of Addiction Societies. <i>CNS Neuroscience and Therapeutics</i> , 2016, 22, 25-37.	1.9	91

#	ARTICLE	IF	CITATIONS
64	Pharmacotherapy for alcohol addiction in a patient with alcoholic cirrhosis and massive upper gastrointestinal bleed: A case study. <i>Drug and Alcohol Review</i> , 2016, 35, 236-239.	1.1	3
65	Patient-Reported Offers of Alcohol Treatment for Primary Care Patients at High-Risk for an Alcohol Use Disorder. <i>Journal of the American Board of Family Medicine</i> , 2016, 29, 682-687.	0.8	2
66	Alcohol Use. <i>Annals of Internal Medicine</i> , 2016, 164, ITC1.	2.0	33
67	Alcoholic Liver Disease in the Asian-Pacific Region with High Prevalence of Chronic Viral Hepatitis. <i>Journal of Medical Ultrasound</i> , 2016, 24, 93-100.	0.2	9
68	Safety and Tolerability of Pharmacological Treatment of Alcohol Dependence: Comprehensive Review of Evidence. <i>Drug Safety</i> , 2016, 39, 627-645.	1.4	43
69	Binge drinking is associated with differences in weekday and weekend adherence in HIV-infected individuals. <i>Drug and Alcohol Dependence</i> , 2016, 159, 174-180.	1.6	11
70	Nalmefene for the treatment of alcohol use disorders: recent data and clinical potential. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 619-626.	0.9	36
71	A Delayed Injection-Site Reaction in a Patient Receiving Extended-Release Naltrexone. <i>Substance Abuse</i> , 2016, 37, 278-280.	1.1	4
72	Pharmacotherapy for Substance Use Disorders. <i>Medical Clinics of North America</i> , 2016, 100, 891-910.	1.1	40
73	Treatment of alcohol use disorders in patients with alcoholic liver disease. <i>Journal of Hepatology</i> , 2016, 65, 618-630.	1.8	156
74	Medication-assisted treatment for opioid dependence in Twelve Step-oriented residential rehabilitation settings. <i>Substance Abuse</i> , 2016, 37, 381-383.	1.1	14
75	A gene-by-sex interaction for nicotine reward: evidence from humanized mice and epidemiology. <i>Translational Psychiatry</i> , 2016, 6, e861-e861.	2.4	16
76	National trends in alcohol pharmacotherapy: Findings from an Australian claims database. <i>Drug and Alcohol Dependence</i> , 2016, 166, 254-257.	1.6	34
77	Proof-of-Concept Study to Assess the Nociceptin Receptor Antagonist <sc>LY</sc>2940094 as a New Treatment for Alcohol Dependence. <i>Alcoholism: Clinical and Experimental Research</i> , 2016, 40, 1935-1944.	1.4	34
78	Primary Care Providers' Interest in Using a Genetic Test to Guide Alcohol Use Disorder Treatment. <i>Journal of Substance Abuse Treatment</i> , 2016, 70, 14-20.	1.5	7
79	Predictive validity of clinical AUDIT-C alcohol screening scores and changes in scores for three objective alcohol-related outcomes in a Veterans Affairs population. <i>Addiction</i> , 2016, 111, 1975-1984.	1.7	43
80	Non-physiological mechanisms influencing disulfiram treatment of alcohol use disorder: A grounded theory study. <i>Drug and Alcohol Dependence</i> , 2016, 165, 126-131.	1.6	2
81	Multifaceted academic detailing program to increase pharmacotherapy for alcohol use disorder: interrupted time series evaluation of effectiveness. <i>Addiction Science &amp; Clinical Practice</i> , 2016, 11, 15.	1.2	40

#	ARTICLE	IF	CITATIONS
82	Nalmefene for the management of alcohol dependence: review on its pharmacology, mechanism of action and meta-analysis on its clinical efficacy. <i>European Neuropsychopharmacology</i> , 2016, 26, 1941-1949.	0.3	77
83	Unhealthy Alcohol Use. <i>Clinics in Liver Disease</i> , 2016, 20, 429-444.	1.0	7
84	Dosage de naltrexone dans les cheveux: intérêt comme marqueur de l'observance des patients au cours du traitement de l'alcoolodépendance. <i>Toxicologie Analytique Et Clinique</i> , 2016, 28, 303-310.	0.1	2
85	Alcohol use disorders in Australia. <i>Internal Medicine Journal</i> , 2016, 46, 1259-1268.	0.5	16
86	An evidence-based approach to screening and providing appropriate interventions for unhealthy alcohol use in primary care settings. <i>Journal of Comparative Effectiveness Research</i> , 2016, 5, 521-524.	0.6	1
87	Weak evidence on nalmefene creates dilemmas for clinicians and poses questions for regulators and researchers. <i>Addiction</i> , 2016, 111, 1477-1487.	1.7	36
89	Office care of substance abuse patients. , 0, , 483-493.		0
90	Evaluation in alcohol use disorders " insights from the nalmefene experience. <i>BMC Medicine</i> , 2016, 14, 119.	2.3	17
91	Anterior Cingulate Glutamate Is Reduced by Acamprosate Treatment in Patients With Alcohol Dependence. <i>Journal of Clinical Psychopharmacology</i> , 2016, 36, 669-674.	0.7	24
92	Alcohol Screening and Intervention Among United States Adults who Attend Ambulatory Healthcare. <i>Journal of General Internal Medicine</i> , 2016, 31, 739-745.	1.3	44
93	Implementation of integrated stepped care for unhealthy alcohol use in HIV clinics. <i>Addiction Science &amp; Clinical Practice</i> , 2016, 11, 1.	1.2	38
94	Treatment-refractory substance use disorder: Focus on alcohol, opioids, and cocaine. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2016, 70, 148-161.	2.5	33
95	HIV primary care providers' Screening, knowledge, attitudes and behaviors related to alcohol interventions. <i>Drug and Alcohol Dependence</i> , 2016, 161, 59-66.	1.6	39
96	Medical Practice Variations in Mental Health and Addictions Care. , 2016, , 161-198.		1
97	Prevention, early intervention, harm reduction, and treatment of substance use in young people. <i>Lancet Psychiatry</i> , the, 2016, 3, 280-296.	3.7	296
98	Unhealthy alcohol use in older adults: Association with readmissions and emergency department use in the 30 days after hospital discharge. <i>Drug and Alcohol Dependence</i> , 2016, 158, 94-101.	1.6	20
99	Drug addiction: targeting dynamic neuroimmune receptor interactions as a potential therapeutic strategy. <i>Current Opinion in Pharmacology</i> , 2016, 26, 131-137.	1.7	48
100	Existing and Future Drugs for the Treatment of the Dark Side of Addiction. <i>Annual Review of Pharmacology and Toxicology</i> , 2016, 56, 299-322.	4.2	90

#	ARTICLE	IF	CITATIONS
101	Alcohol use disorders. <i>Lancet</i> , The, 2016, 387, 988-998.	6.3	277
102	Alcohol-Related Diagnoses and All-Cause Hospitalization Among HIV-Infected and Uninfected Patients: A Longitudinal Analysis of United States Veterans from 1997 to 2011. <i>AIDS and Behavior</i> , 2016, 20, 555-564.	1.4	25
103	Socioeconomic and geographic disparities in access to pharmacotherapy for alcohol dependence. <i>Journal of Substance Abuse Treatment</i> , 2017, 74, 23-25.	1.5	17
104	Feasibility and safety of extended-release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot/feasibility randomized trial. <i>Addiction</i> , 2017, 112, 1036-1044.	1.7	51
105	Nalmefene Reduces Reward Anticipation in Alcohol Dependence: An Experimental Functional Magnetic Resonance Imaging Study. <i>Biological Psychiatry</i> , 2017, 81, 941-948.	0.7	32
106	Posttraumatic Stress Disorder and Alcohol Use Disorder: A Critical Review of Pharmacologic Treatments. <i>Alcoholism: Clinical and Experimental Research</i> , 2017, 41, 226-237.	1.4	61
107	Review article: pharmacotherapy for alcohol dependence – the why, the what and the wherefore. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 865-882.	1.9	68
108	New paradigms in management of alcoholic hepatitis: a review. <i>Hepatology International</i> , 2017, 11, 255-267.	1.9	21
109	A Systematic Review of Naltrexone for Attenuating Alcohol Consumption in Women with Alcohol Use Disorders. <i>Alcoholism: Clinical and Experimental Research</i> , 2017, 41, 466-472.	1.4	16
110	Altering ethanol pharmacokinetics to treat alcohol use disorder: Can you teach an old dog new tricks?. <i>Journal of Psychopharmacology</i> , 2017, 31, 812-818.	2.0	10
111	A Double-Blind Randomized Placebo-Controlled Trial of Oral Naltrexone for Heavy-Drinking Smokers Seeking Smoking Cessation Treatment. <i>Alcoholism: Clinical and Experimental Research</i> , 2017, 41, 1201-1211.	1.4	20
112	Predictors of Naltrexone Response in a Randomized Trial: Reward-Related Brain Activation, OPRM1 Genotype, and Smoking Status. <i>Neuropsychopharmacology</i> , 2017, 42, 2640-2653.	2.8	82
113	Emerging pharmacotherapies for alcohol use disorder. <i>Neuropharmacology</i> , 2017, 122, 244-253.	2.0	45
114	The identification and management of substance use disorders in anesthesiologists. <i>Canadian Journal of Anaesthesia</i> , 2017, 64, 211-218.	0.7	13
115	Metabolomics biomarkers to predict acamprosate treatment response in alcohol-dependent subjects. <i>Scientific Reports</i> , 2017, 7, 2496.	1.6	24
116	Nalmefene in Alcohol Use Disorder Subjects with Psychiatric Comorbidity: A Naturalistic Study. <i>Advances in Therapy</i> , 2017, 34, 1636-1649.	1.3	13
117	Naltrexone efficacy in treating alcohol-use disorder in individuals with comorbid psychosis: a systematic review. <i>Therapeutic Advances in Psychopharmacology</i> , 2017, 7, 211-224.	1.2	12
118	As Hopes Have Flown Before: Toward the Rational Design of Treatments for Alcohol Use Disorder. <i>Biological Psychiatry</i> , 2017, 81, e79-e81.	0.7	0

#	ARTICLE	IF	CITATIONS
119	The endocannabinoid system as a target for addiction treatment: Trials and tribulations. <i>Neuropharmacology</i> , 2017, 124, 73-83.	2.0	77
120	Screening and Counseling for Unhealthy Alcohol Use in Primary Care Settings. <i>Medical Clinics of North America</i> , 2017, 101, 823-837.	1.1	9
121	Predischarge Injectable Versus Oral Naltrexone to Improve Postdischarge Treatment Engagement Among Hospitalized Veterans with Alcohol Use Disorder: A Randomized Pilot Proof-of-Concept Study. <i>Alcoholism: Clinical and Experimental Research</i> , 2017, 41, 1352-1360.	1.4	19
122	Barriers to and facilitators of pharmacotherapy for alcohol use disorder in VA residential treatment programs. <i>Journal of Substance Abuse Treatment</i> , 2017, 77, 38-43.	1.5	22
123	Management of precipitated opiate withdrawal syndrome induced by nalmefene mistakenly prescribed in opiate-dependent patients: a review for clinicians. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 669-677.	1.5	7
124	Challenges and Gaps in Understanding Substance Use Problems in Transitional Age Youth. <i>Child and Adolescent Psychiatric Clinics of North America</i> , 2017, 26, 253-269.	1.0	14
125	Guidelines for biological treatment of substance use and related disorders, part 1: Alcoholism, first revision. <i>World Journal of Biological Psychiatry</i> , 2017, 18, 86-119.	1.3	55
126	Reduced Drinking in Alcohol Dependence Treatment, What Is the Evidence?. <i>European Addiction Research</i> , 2017, 23, 219-230.	1.3	67
127	Thirty- Versus Ten-Day Diazepam Treatment for Alcohol Detoxification and a Comparison of Drinking Patterns, Craving, and Anxiety for up to 12 Weeks. <i>Journal of Clinical Psychopharmacology</i> , 2017, 37, 722-728.	0.7	6
128	Effects of a multifaceted implementation intervention to increase utilization of pharmacological treatments for alcohol use disorders in the US Veterans Health Administration. <i>Journal of Substance Abuse Treatment</i> , 2017, 82, 107-112.	1.5	25
129	Targeting harmful use of alcohol for prevention and treatment of tuberculosis: a call for action. <i>European Respiratory Journal</i> , 2017, 50, 1700946.	3.1	9
130	Treating the "Wake-up Call" of Alcohol Use. <i>JAMA Internal Medicine</i> , 2017, 177, 1849.	2.6	2
131	Medications for substance use disorders (SUD): emerging approaches. <i>Expert Opinion on Emerging Drugs</i> , 2017, 22, 301-315.	1.0	13
132	The Glycine Receptor "A Functionally Important Primary Brain Target of Ethanol. <i>Alcoholism: Clinical and Experimental Research</i> , 2017, 41, 1816-1830.	1.4	43
133	Collaborative Care for Opioid and Alcohol Use Disorders in Primary Care. <i>JAMA Internal Medicine</i> , 2017, 177, 1480.	2.6	151
134	Systematic review: Baclofen dosing protocols for alcohol use disorders used in observational studies. <i>European Neuropsychopharmacology</i> , 2017, 27, 1077-1089.	0.3	15
135	Canadian Schizophrenia Guidelines: Schizophrenia and Other Psychotic Disorders with Coexisting Substance Use Disorders. <i>Canadian Journal of Psychiatry</i> , 2017, 62, 624-634.	0.9	80
136	Cost-Effectiveness of Interventions for the Treatment of Alcohol and Other Substance Use Disorders. , 2017, , 323-338.		1



#	ARTICLE	IF	CITATIONS
137	Alcohol-Related Mortality in Patients With Psoriasis. <i>JAMA Dermatology</i> , 2017, 153, 1256.	2.0	36
138	Implementation and Quality Improvement of a Screening and Counseling Program for Unhealthy Alcohol Use in an Academic General Internal Medicine Practice. <i>Journal for Healthcare Quality: Official Publication of the National Association for Healthcare Quality</i> , 2017, 39, 15-27.	0.3	7
139	Guidelines for the understanding and management of pain in chronic pancreatitis. <i>Pancreatology</i> , 2017, 17, 720-731.	0.5	214
140	Variation in receipt of pharmacotherapy for alcohol use disorders across racial/ethnic groups: A national study in the U.S. Veterans Health Administration. <i>Drug and Alcohol Dependence</i> , 2017, 178, 527-533.	1.6	47
141	Effects of naltrexone are influenced by childhood adversity during negative emotional processing in addiction recovery. <i>Translational Psychiatry</i> , 2017, 7, e1054-e1054.	2.4	18
142	At-Risk Alcohol Use is Associated with Antiretroviral Treatment Nonadherence Among Adults Living with HIV/AIDS. <i>Alcoholism: Clinical and Experimental Research</i> , 2017, 41, 1518-1525.	1.4	19
143	Acceptability and feasibility of a randomized clinical trial of oral naltrexone vs. placebo for women living with HIV infection: Study design challenges and pilot study results. <i>Contemporary Clinical Trials</i> , 2017, 60, 72-77.	0.8	8
145	Co-use of Alcohol and Cannabis: A Review. <i>Current Addiction Reports</i> , 2017, 4, 184-193.	1.6	220
146	Patient-centered primary care for adults at high risk for AUDs: the Choosing Healthier Drinking Options In primary Care (CHOICE) trial. <i>Addiction Science &amp; Clinical Practice</i> , 2017, 12, 15.	1.2	14
147	Naloxone effects on extinction of ethanol- and cocaine-induced conditioned place preference in mice. <i>Psychopharmacology</i> , 2017, 234, 2747-2759.	1.5	11
148	Pharmacotherapy of alcoholism – an update on approved and off-label medications. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1187-1199.	0.9	81
149	Dysregulation of brain stress systems mediates compulsive alcohol drinking. <i>Current Opinion in Behavioral Sciences</i> , 2017, 13, 85-90.	2.0	48
150	Making the hard work of recovery more attractive for those with substance use disorders. <i>Addiction</i> , 2017, 112, 751-757.	1.7	106
151	Care of the Alcoholic Patient. , 2017, , 755-771.		0
152	Effects of naltrexone on alcohol self-administration and craving: meta-analysis of human laboratory studies. <i>Addiction Biology</i> , 2017, 22, 1515-1527.	1.4	73
153	Novel Applications of Metabolomics in Personalized Medicine: A Mini-Review. <i>Molecules</i> , 2017, 22, 1173.	1.7	76
154	Evaluation of a Pilot Implementation to Integrate Alcohol-Related Care within Primary Care. <i>International Journal of Environmental Research and Public Health</i> , 2017, 14, 1030.	1.2	48
155	Comparison of DSM-IV and DSM-5 criteria for alcohol use disorders in VA primary care patients with frequent heavy drinking enrolled in a trial. <i>Addiction Science &amp; Clinical Practice</i> , 2017, 12, 17.	1.2	28

#	ARTICLE	IF	CITATIONS
156	Protective effect of arctigenin on ethanol-induced neurotoxicity in PC12 cells. <i>Molecular Medicine Reports</i> , 2017, 15, 2235-2240.	1.1	16
157	GABA and Glutamate Synaptic Coadaptations to Chronic Ethanol in the Striatum. <i>Handbook of Experimental Pharmacology</i> , 2018, 248, 79-112.	0.9	6
158	Predictors of Treatment Referral After AUDIT-C Screening for Heavy Drinking. <i>Addictive Disorders and Their Treatment</i> , 2018, 17, 124-133.	0.5	1
159	Insomnia in Alcohol-Dependent Patients: Prevalence, Risk Factors and Acamprosate Effect: An Individual Patient Data Meta-Analysis. <i>Alcohol and Alcoholism</i> , 2018, 53, 611-618.	0.9	15
160	Distinct Accumbens Shell Output Pathways Promote versus Prevent Relapse to Alcohol Seeking. <i>Neuron</i> , 2018, 98, 512-520.e6.	3.8	59
161	Effects of motivational interviewing fidelity on substance use treatment engagement in primary care. <i>Journal of Substance Abuse Treatment</i> , 2018, 87, 64-69.	1.5	12
162	Pharmacoproteomics Profile in Response to Acamprosate Treatment of an Alcoholism Animal Model. <i>Proteomics</i> , 2018, 18, e1700417.	1.3	8
163	The OPRM1 A118G polymorphism: converging evidence against associations with alcohol sensitivity and consumption. <i>Neuropsychopharmacology</i> , 2018, 43, 1530-1538.	2.8	22
164	Childhood Adversity and Hazardous Drinking: The Mediating Role of Attachment Insecurity. <i>Substance Use and Misuse</i> , 2018, 53, 1387-1398.	0.7	5
165	GLP-1 signaling and alcohol-mediated behaviors; preclinical and clinical evidence. <i>Neuropharmacology</i> , 2018, 136, 343-349.	2.0	37
166	ACG Clinical Guideline: Alcoholic Liver Disease. <i>American Journal of Gastroenterology</i> , 2018, 113, 175-194.	0.2	530
167	Systematic Review of Combined Pharmacotherapy for the Treatment of Alcohol Use Disorder in Patients Without Comorbid Conditions. <i>CNS Drugs</i> , 2018, 32, 13-31.	2.7	9
168	Real-time assessment of alcohol craving and naltrexone treatment responsiveness in a randomized clinical trial. <i>Addictive Behaviors</i> , 2018, 83, 72-78.	1.7	11
169	Alcohol-related and mental health care for patients with unhealthy alcohol use and posttraumatic stress disorder in a National Veterans Affairs cohort. <i>Journal of Substance Abuse Treatment</i> , 2018, 85, 1-9.	1.5	17
170	Alcohol and Opioid Use, Co-Use, and Chronic Pain in the Context of the Opioid Epidemic: A Critical Review. <i>Alcoholism: Clinical and Experimental Research</i> , 2018, 42, 478-488.	1.4	163
171	Genome-wide and digital polymerase chain reaction epigenetic assessments of alcohol consumption. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2018, 177, 479-488.	1.1	23
172	Integration of a Clinical Pharmacy Specialist into a Substance use Disorder Intensive Outpatient Treatment Program to Improve Prescribing Rates of Alcohol use Disorder Pharmacotherapy. <i>Substance Abuse</i> , 2018, 39, 190-192.	1.1	15
173	Pharmacotherapy for Alcohol Use Disorder. <i>Medical Clinics of North America</i> , 2018, 102, 653-666.	1.1	9

#	ARTICLE	IF	CITATIONS
174	Alcohol-Related Nurse Care Management in Primary Care. <i>JAMA Internal Medicine</i> , 2018, 178, 613.	2.6	33
175	Effectiveness of community psychosocial and pharmacological treatments for alcohol use disorder: A national observational cohort study in England. <i>Drug and Alcohol Dependence</i> , 2018, 186, 60-67.	1.6	10
176	Canadian Network for Mood and Anxiety Treatments (<scp>CANMAT</scp>) and International Society for Bipolar Disorders (<scp>ISBD</scp>) 2018 guidelines for the management of patients with bipolar disorder. <i>Bipolar Disorders</i> , 2018, 20, 97-170.	1.1	1,079
177	Receipt of Pharmacotherapy for Alcohol Use Disorder by Male Justice-Involved U.S. Veterans Health Administration Patients. <i>Criminal Justice Policy Review</i> , 2018, 29, 875-890.	0.5	4
178	Barriers to initiation of extended release naltrexone among HIV-infected adults with alcohol use disorders. <i>Journal of Substance Abuse Treatment</i> , 2018, 85, 34-37.	1.5	10
179	Mecamylamine treatment for alcohol dependence: a randomized controlled trial. <i>Addiction</i> , 2018, 113, 6-14.	1.7	23
180	Barriers to and Facilitators of Alcohol Use Disorder Pharmacotherapy in Primary Care: A Qualitative Study in Five VA Clinics. <i>Journal of General Internal Medicine</i> , 2018, 33, 258-267.	1.3	68
181	The cost-effectiveness of therapies to treat alcohol use disorders. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2018, 18, 43-49.	0.7	19
182	Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate. <i>Addiction</i> , 2018, 113, 220-237.	1.7	117
183	Addressing unhealthy alcohol use among people living with HIV: recent advances and research directions. <i>Current Opinion in Infectious Diseases</i> , 2018, 31, 1-7.	1.3	30
184	Gabapentin for the treatment of alcohol use disorder. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 113-124.	1.9	70
185	Low-threshold extended-release naltrexone for high utilizers of public services with severe alcohol use disorder: A pilot study. <i>Journal of Substance Abuse Treatment</i> , 2018, 85, 109-115.	1.5	6
186	Precision Medicine in Alcohol Dependence: A Controlled Trial Testing Pharmacotherapy Response Among Reward and Relief Drinking Phenotypes. <i>Neuropsychopharmacology</i> , 2018, 43, 891-899.	2.8	91
187	Alcohol addiction - the safety of available approved treatment options. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 169-177.	1.0	33
188	Applying American Society of Addiction Medicine Performance Measures in Commercial Health Insurance and Services Data. <i>Journal of Addiction Medicine</i> , 2018, 12, 287-294.	1.4	19
189	Alcohol Withdrawal Management and Relapse Prevention in Pregnancy. <i>Canadian Journal of Addiction</i> , 2018, 9, 32-41.	0.2	1
190	Screening and Behavioral Counseling Interventions to Reduce Unhealthy Alcohol Use in Adolescents and Adults. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 1910.	3.8	150
191	Prisoners as Patients: The Opioid Epidemic, Medication-Assisted Treatment, and the Eighth Amendment. <i>Journal of Law, Medicine and Ethics</i> , 2018, 46, 252-267.	0.4	7

#	ARTICLE	IF	CITATIONS
193	Acceptability of pharmacotherapy for hazardous alcohol use among men who have sex with men: Findings from a qualitative study. <i>Addictive Behaviors Reports</i> , 2018, 8, 122-127.	1.0	1
194	Study protocol: a cluster-randomized trial implementing Sustained Patient-centered Alcohol-related Care (SPARC trial). <i>Implementation Science</i> , 2018, 13, 108.	2.5	41
195	Cost-Effectiveness Analysis of Genotype-Guided Treatment Allocation in Patients with Alcohol Use Disorders Using Naltrexone or Acamprosate, Using a Modeling Approach. <i>European Addiction Research</i> , 2018, 24, 245-254.	1.3	9
196	Effects of high-dose baclofen on cue reactivity in alcohol dependence: A randomized, placebo-controlled pharmacofMRI study. <i>European Neuropsychopharmacology</i> , 2018, 28, 1206-1216.	0.3	24
197	Receipt of alcohol-related care among patients with HCV and unhealthy alcohol use. <i>Drug and Alcohol Dependence</i> , 2018, 188, 79-85.	1.6	21
198	Pharmacotherapy for Alcohol Use Disorder in the Context of Liver Disease. <i>Current Addiction Reports</i> , 2018, 5, 287-296.	1.6	7
200	Office-Based Addiction Treatment in Primary Care. <i>Medical Clinics of North America</i> , 2018, 102, 635-652.	1.1	17
201	Overcoming the "Valley of Death" in Medications Development for Alcohol Use Disorder. <i>Alcoholism: Clinical and Experimental Research</i> , 2018, 42, 1612-1622.	1.4	30
202	Medications for Alcohol and Opioid Use Disorders and Risk of Suicidal Behavior, Accidental Overdoses, and Crime. <i>American Journal of Psychiatry</i> , 2018, 175, 970-978.	4.0	51
203	Predictors of treatment initiation for alcohol use disorders in primary care. <i>Drug and Alcohol Dependence</i> , 2018, 191, 56-62.	1.6	12
204	Prescribed sedative and other psychotropic medication use among clients attending alcohol and other drug treatment. <i>Drug and Alcohol Review</i> , 2018, 37, 738-742.	1.1	8
205	Efficacy and safety of sodium oxybate in alcohol-dependent patients with a very high drinking risk level. <i>Addiction Biology</i> , 2018, 23, 969-986.	1.4	59
206	N-acetyl cysteine in the treatment of alcohol use disorder in patients with liver disease: Rationale for further research. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 667-675.	1.9	20
207	Pharmacological and Psychological Treatments for Comorbid Alcohol Use Disorder and Depressive Disorder: a Review. <i>Current Addiction Reports</i> , 2018, 5, 312-322.	1.6	6
208	Differences in Perceptions of and Practices Regarding Treatment of Alcohol Use Disorders Among VA Primary Care Providers in Urban and Rural Clinics. <i>Journal of Rural Health</i> , 2018, 34, 359-368.	1.6	13
209	Pharmacological treatments for opiate and alcohol addiction: A historical perspective of the last 50 years. <i>European Journal of Pharmacology</i> , 2018, 836, 89-101.	1.7	21
210	Prevalence and correlates of hazardous alcohol consumption and binge drinking among men who have sex with men (MSM) in San Francisco. <i>PLoS ONE</i> , 2018, 13, e0202170.	1.1	22
211	Efficacy of Ketamine in the Treatment of Substance Use Disorders: A Systematic Review. <i>Frontiers in Psychiatry</i> , 2018, 9, 277.	1.3	76

#	ARTICLE	IF	CITATIONS
212	Predictors of Daily Adherence to Naltrexone for Alcohol Use Disorder Treatment During a Mobile Health Intervention. <i>Annals of Behavioral Medicine</i> , 2018, 52, 787-797.	1.7	14
213	Medications for Alcohol Use Disorder and Predicting Severe Withdrawal. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 766.	3.8	6
214	Diagnosis and Pharmacotherapy of Alcohol Use Disorder. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 815.	3.8	382
215	Baclofen for alcohol use disorder—a systematic meta-analysis. <i>Acta Psychiatrica Scandinavica</i> , 2018, 138, 232-242.	2.2	59
216	Efficacy of Extended-Release Naltrexone on HIV-Related and Drinking Outcomes Among HIV-Positive Patients: A Randomized-Controlled Trial. <i>AIDS and Behavior</i> , 2019, 23, 211-221.	1.4	26
217	Mobile alcohol biosensors and pharmacotherapy development research. <i>Alcohol</i> , 2019, 81, 149-160.	0.8	17
218	Unmet mental health and substance use treatment needs among older homeless adults: Results from the HOPE HOME Study. <i>Journal of Community Psychology</i> , 2019, 47, 1893-1908.	1.0	18
220	Reduction in Drinking was Associated With Improved Clinical Outcomes in Women With HIV Infection and Unhealthy Alcohol Use: Results From a Randomized Clinical Trial of Oral Naltrexone Versus Placebo. <i>Alcoholism: Clinical and Experimental Research</i> , 2019, 43, 1790-1800.	1.4	17
221	Pharmacogenetics of alcohol use disorder treatments: an update. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 553-564.	1.5	23
222	Outcome Assessment in Trials of Pharmacological Treatments for Alcohol Use Disorders: Fair and Strict Testing. <i>CNS Drugs</i> , 2019, 33, 649-657.	2.7	5
223	&lt;p&gt;Pharmacogenetics of alcohol addiction: current perspectives&lt;/p&gt;. <i>The Application of Clinical Genetics</i> , 2019, Volume 12, 131-140.	1.4	10
224	Translating Neurobiology into Practice in Tobacco, Alcohol, Drug, and Behavioral Addictions. <i>Handbook of Behavioral Neuroscience</i> , 2019, 29, 389-401.	0.7	0
225	Medications to Treat Mental Health and Substance Abuse Disorders. , 2019, , 790-806.		0
226	Its complicated: The relationship between alcohol and microglia in the search for novel pharmacotherapeutic targets for alcohol use disorders. <i>Progress in Molecular Biology and Translational Science</i> , 2019, 167, 179-221.	0.9	30
227	Developing neuroscience-based treatments for alcohol addiction: A matter of choice?. <i>Translational Psychiatry</i> , 2019, 9, 255.	2.4	65
228	Probenecid Reduces Alcohol Drinking in Rodents. Is Pannexin1 a Novel Therapeutic Target for Alcohol Use Disorder?. <i>Alcohol and Alcoholism</i> , 2019, 54, 497-502.	0.9	8
229	The selective Î²-opioid receptor antagonist JD1c attenuates the alcohol deprivation effect in rats. <i>European Neuropsychopharmacology</i> , 2019, 29, 1386-1396.	0.3	7
230	Integrated stepped alcohol treatment for patients with HIV and liver disease: A randomized trial. <i>Journal of Substance Abuse Treatment</i> , 2019, 106, 97-106.	1.5	14

#	ARTICLE	IF	CITATIONS
231	Efficacy and acceptability of varenicline for alcoholism: A systematic review and meta-analysis of randomized-controlled trials. <i>Drug and Alcohol Dependence</i> , 2019, 205, 107631.	1.6	19
232	Prevention, screening, and treatment for heavy drinking and alcohol use disorder. <i>Lancet Psychiatry</i> , 2019, 6, 1054-1067.	3.7	82
233	Inpatient Addiction Medicine Consultation and Post-Hospital Substance Use Disorder Treatment Engagement: a Propensity-Matched Analysis. <i>Journal of General Internal Medicine</i> , 2019, 34, 2796-2803.	1.3	132
234	Alcohol use disorders. <i>Lancet</i> , 2019, 394, 781-792.	6.3	382
235	Advances in the science and treatment of alcohol use disorder. <i>Science Advances</i> , 2019, 5, eaax4043.	4.7	265
236	Neurobiological Basis of Craving and Anti-Craving Medications. <i>Journal of Korean Neuropsychiatric Association</i> , 2019, 58, 167.	0.2	0
237	Estimating Long-Term Drinking Patterns for People with Lifetime Alcohol Use Disorder. <i>Medical Decision Making</i> , 2019, 39, 765-780.	1.2	7
238	Cannabidiol as a Novel Candidate Alcohol Use Disorder Pharmacotherapy: A Systematic Review. <i>Alcoholism: Clinical and Experimental Research</i> , 2019, 43, 550-563.	1.4	56
239	Effect of Assertive Community Treatment for Patients with Substance Use Disorder: A Systematic Review. <i>European Addiction Research</i> , 2019, 25, 56-67.	1.3	19
240	Gender Disparities in Alcohol Use Disorder Treatment Among Privately Insured Patients with Alcohol-Associated Cirrhosis. <i>Alcoholism: Clinical and Experimental Research</i> , 2019, 43, 334-341.	1.4	56
241	Receipt of pharmacotherapy for alcohol use disorder by justice-involved women in the Veterans Health Administration. <i>Addiction Science &amp; Clinical Practice</i> , 2019, 14, 1.	1.2	11
242	Low levels of initiation, engagement, and retention in substance use disorder treatment including pharmacotherapy among HIV-infected and uninfected veterans. <i>Journal of Substance Abuse Treatment</i> , 2019, 103, 23-32.	1.5	16
243	Treating Alcohol Use Disorder in U.S. Veterans: The Role of Traumatic Brain Injury. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2019, 31, 319-327.	0.9	4
244	Extended-release vs. oral naltrexone for alcohol dependence treatment in primary care (XON). <i>Contemporary Clinical Trials</i> , 2019, 81, 102-109.	0.8	9
245	The Effect of High-Frequency Repetitive Transcranial Magnetic Stimulation on Emotion Processing, Reappraisal, and Craving in Alcohol Use Disorder Patients and Healthy Controls: A Functional Magnetic Resonance Imaging Study. <i>Frontiers in Psychiatry</i> , 2019, 10, 272.	1.3	22
246	Naltrexone effects on subjective responses to alcohol in the human laboratory: A systematic review and meta-analysis. <i>Addiction Biology</i> , 2019, 24, 1138-1152.	1.4	38
247	Impact of Alcohol Use on Pain. , 2019, , 1179-1182.		0
248	Building better strategies to develop new medications in Alcohol Use Disorder: Learning from past success and failure to shape a brighter future. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 103, 384-398.	2.9	13

#	ARTICLE	IF	CITATIONS
249	Primary care engagement is associated with increased pharmacotherapy prescribing for alcohol use disorder (AUD). <i>Addiction Science &amp; Clinical Practice</i> , 2019, 14, 19.	1.2	14
250	Design of a randomized controlled trial examining the efficacy of oxytocin to enhance alcohol behavioral couple therapy. <i>Contemporary Clinical Trials</i> , 2019, 82, 1-8.	0.8	5
251	Treatment for Substance Use Disorder With Co-Occurring Mental Illness. <i>Focus (American Psychiatric)</i> Tj ETQq0 0 0 rgBT /Overlock 10 T	0.4	28
252	Patient Perspectives on Alcohol use Disorder Pharmacotherapy and Integration of Treatment into Primary Care Settings. <i>Substance Abuse</i> , 2019, 40, 501-509.	1.1	12
253	Gender Differences in Use of Alcohol Treatment Services and Reasons for Nonuse in a National Sample. <i>Alcoholism: Clinical and Experimental Research</i> , 2019, 43, 722-731.	1.4	52
254	Possible Benefit and Validity of Supplements for Alcohol Use Disorder. <i>Alcoholism: Clinical and Experimental Research</i> , 2019, 43, 780-782.	1.4	2
255	Efficacy of Pharmacological Interventions in Targeting Decision-Making Impairments across Substance and Behavioral Addictions. <i>Neuropsychology Review</i> , 2019, 29, 93-102.	2.5	7
256	Strategies to increase implementation of pharmacotherapy for alcohol use disorders: a structured review of care delivery and implementation interventions. <i>Addiction Science &amp; Clinical Practice</i> , 2019, 14, 6.	1.2	25
257	Differences in Receipt of Alcohol-Related Care Across Rurality Among VA Patients Living With HIV With Unhealthy Alcohol Use. <i>Journal of Rural Health</i> , 2019, 35, 341-353.	1.6	14
258	Clinical Predictors of Response to Baclofen in the Treatment of Alcohol use Disorder: Results from the BacALD Trial. <i>Alcohol and Alcoholism</i> , 2019, 54, 272-278.	0.9	9
259	Machine learning vs addiction therapists: A pilot study predicting alcohol dependence treatment outcome from patient data in behavior therapy with adjunctive medication. <i>Journal of Substance Abuse Treatment</i> , 2019, 99, 156-162.	1.5	20
260	Integrated cognitive behavioral therapy for ADHD in adult substance use disorder patients: Results of a randomized clinical trial. <i>Drug and Alcohol Dependence</i> , 2019, 197, 28-36.	1.6	32
262	Overcoming Alcohol Addiction in Patients with Alcohol-Related Liver Disease. <i>Current Hepatology Reports</i> , 2019, 18, 73-80.	0.4	0
263	Therapeutic challenges for concurrent ethanol and nicotine consumption: naltrexone and varenicline fail to alter simultaneous ethanol and nicotine intake by female alcohol-preferring (P) rats. <i>Psychopharmacology</i> , 2019, 236, 1887-1900.	1.5	17
264	Medicine, with a focus on physician assistants: Addressing substance use in the 21st century. <i>Substance Abuse</i> , 2019, 40, 405-411.	1.1	4
265	The effects of nalmefene on emotion processing in alcohol use disorder " A randomized, controlled fMRI study. <i>European Neuropsychopharmacology</i> , 2019, 29, 1442-1452.	0.3	14
266	Beyond Brief Intervention: Pharmacologic Management of Alcohol Use Disorder. <i>Journal for Nurse Practitioners</i> , 2019, 15, 627-630.	0.4	1
267	Article Commentary: Medicine, with a Focus on Physicians: Addressing Substance use in the 21st Century. <i>Substance Abuse</i> , 2019, 40, 396-404.	1.1	7

#	ARTICLE	IF	CITATIONS
268	Medication Development for Alcohol Use Disorder: A Focus on Clinical Studies. Handbook of Experimental Pharmacology, 2019, 258, 443-462.	0.9	19
269	Selecting an appropriate alcohol pharmacotherapy. Current Opinion in Psychiatry, 2019, 32, 266-274.	3.1	12
270	Prioritizing Evidence-based Interventions for Dissemination and Implementation Investments. Medical Care, 2019, 57, S272-S277.	1.1	7
271	Topiramate Pharmacotherapy for Alcohol Use Disorder and Other Addictions: A Narrative Review. Journal of Addiction Medicine, 2019, 13, 7-22.	1.4	25
272	Prospects for pharmacotherapies to treat alcohol use disorder. Current Opinion in Psychiatry, 2019, 32, 255-265.	3.1	25
273	Conquering the Craving. Journal of Christian Nursing: A Quarterly Publication of Nurses Christian Fellowship, 2019, 36, 148-156.	0.1	1
274	Pharmacologic management and prevention of acute pancreatitis. Current Opinion in Gastroenterology, 2019, 35, 460-467.	1.0	18
275	False Positive Urine Drug Screens in Patients Receiving Oral Naltrexone. Canadian Journal of Addiction, 2019, 10, 25-26.	0.2	1
276	State-of-the-Art Treatment of Alcohol Use Disorder. , 2019, , 123-135.		0
277	Trauma and Addictionâ€”How to Treat Co-occurring PTSD and Substance Use Disorders. , 2019, , 189-196.		1
278	Functional Assessment and Treatment of Alcohol Use Disorders. , 2019, , 219-232.		0
279	Pharmacological Treatments for Disordered Gambling: A Meta-analysis. Journal of Gambling Studies, 2019, 35, 415-445.	1.1	34
280	Unhealthy Alcohol Use in Primary Careâ€”The Elephant in the Examination Room. JAMA Internal Medicine, 2019, 179, 9.	2.6	10
281	Gut-brain axis and addictive disorders: A review with focus on alcohol and drugs of abuse. , 2019, 196, 1-14.		58
282	Clinical Aspects of Alcoholic Liver Disease. , 2019, , 3-21.		0
283	Influence of comorbid drug use disorder on receipt of evidence-based treatment for alcohol use disorder among VA patients with alcohol use disorder and Hepatitis C and/or HIV. Drug and Alcohol Dependence, 2019, 194, 288-295.	1.6	8
284	A Randomized, Double-blind, Placebo-controlled Trial of Citicoline in Patients with Alcohol Use Disorder. Alcoholism: Clinical and Experimental Research, 2019, 43, 317-323.	1.4	7
285	Alcohol Use Disorders in Alcoholic Liver Disease. Clinics in Liver Disease, 2019, 23, 55-69.	1.0	16



#	ARTICLE	IF	CITATIONS
286	Association Between Gabapentin Receipt for Any Indication and Alcohol Use Disorders Identification Testâ€™ Consumption Scores Among Clinical Subpopulations With and Without Alcohol Use Disorder. <i>Alcoholism: Clinical and Experimental Research</i> , 2019, 43, 522-530.	1.4	12
287	Serious adverse events reported in placebo randomised controlled trials of oral naltrexone: a systematic review and meta-analysis. <i>BMC Medicine</i> , 2019, 17, 10.	2.3	37
288	The Use of Baclofen as a Treatment for Alcohol Use Disorder: A Clinical Practice Perspective. <i>Frontiers in Psychiatry</i> , 2018, 9, 708.	1.3	47
289	A Pilot Randomized, Placebo-Controlled Trial of Glycine for Treatment of Schizophrenia and Alcohol Dependence. <i>Journal of Dual Diagnosis</i> , 2019, 15, 46-55.	0.7	9
290	WFSBP and IAWMH Guidelines for the treatment of alcohol use disorders in pregnant women. <i>World Journal of Biological Psychiatry</i> , 2019, 20, 17-50.	1.3	31
291	State-of-the-art behavioral and pharmacological treatments for alcohol use disorder. <i>American Journal of Drug and Alcohol Abuse</i> , 2019, 45, 124-140.	1.1	76
292	Dopamine and opioid systems adaptation in alcoholism revisited: Convergent evidence from positron emission tomography and postmortem studies. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 106, 141-164.	2.9	32
293	Animal models of binge drinking, current challenges to improve face validity. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 106, 112-121.	2.9	35
294	The novel ghrelin receptor inverse agonist PF-5190457 administered with alcohol: preclinical safety experiments and a phase 1b human laboratory study. <i>Molecular Psychiatry</i> , 2020, 25, 461-475.	4.1	90
295	Very Low Frequency of Drug Therapy of Alcohol Dependence in Germany â€™ Analysis of Data of A Statutory Health Insurance. <i>Pharmacopsychiatry</i> , 2020, 53, 37-39.	1.7	4
296	A novel telehealth platform for alcohol use disorder treatment: preliminary evidence of reductions in drinking. <i>American Journal of Drug and Alcohol Abuse</i> , 2020, 46, 297-303.	1.1	10
297	Combined administration of varenicline and bupropion produces additive effects on accumbal dopamine and abolishes the alcohol deprivation effect in rats. <i>Addiction Biology</i> , 2020, 25, e12807.	1.4	12
298	Update on the management of alcohol use disorders. <i>BJ Psych Advances</i> , 2020, 26, 82-91.	0.5	2
299	Repetitive transcranial magnetic stimulation targeting the insular cortex for reduction of heavy drinking in treatment-seeking alcohol-dependent subjects: a randomized controlled trial. <i>Neuropsychopharmacology</i> , 2020, 45, 842-850.	2.8	42
300	Alcohol Use and Longâ€™Term Outcomes Among U.S. Veterans Who Received Directâ€™Acting Antivirals for Hepatitis C Treatment. <i>Hepatology Communications</i> , 2020, 4, 314-324.	2.0	11
301	Predictors of initiation of and retention on medications for alcohol use disorder among people living with and without HIV. <i>Journal of Substance Abuse Treatment</i> , 2020, 109, 14-22.	1.5	16
302	Prevalence of documented alcohol and opioid use disorder diagnoses and treatments in a regional primary care practice-based research network. <i>Journal of Substance Abuse Treatment</i> , 2020, 110, 18-27.	1.5	30
303	Rat Models of Alcohol Use Disorder. , 2020, , 967-986.		4

#	ARTICLE	IF	CITATIONS
304	Craving mediates the effect of impulsivity on lapse-risk during alcohol use disorder treatment. <i>Addictive Behaviors</i> , 2020, 105, 106286.	1.7	13
305	Safety of nalmefene for the treatment of alcohol use disorder: an update. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 9-17.	1.0	3
306	Cannabinoids and the Microbiotaâ€“Gutâ€“Brain Axis: Emerging Effects of Cannabidiol and Potential Applications to Alcohol Use Disorders. <i>Alcoholism: Clinical and Experimental Research</i> , 2020, 44, 340-353.	1.4	20
307	Five Priority Areas for Improving Medications Development for Alcohol Use Disorder and Promoting Their Routine Use in Clinical Practice. <i>Alcoholism: Clinical and Experimental Research</i> , 2020, 44, 23-35.	1.4	17
308	Alcohol-mediated behaviours and the gut-brain axis; with focus on glucagon-like peptide-1. <i>Brain Research</i> , 2020, 1727, 146562.	1.1	23
309	Acceptability and efficacy of naltrexone for criminal justiceâ€“involved individuals with opioid use disorder: a systematic review and metaâ€“analysis. <i>Addiction</i> , 2020, 115, 1413-1425.	1.7	17
310	Outcomes of deep brain stimulation surgery for substance use disorder: a systematic review. <i>Neurosurgical Review</i> , 2021, 44, 1967-1976.	1.2	24
311	Gut Microbiota-Induced Changes in Î²-Hydroxybutyrate Metabolism Are Linked to Altered Sociability and Depression in Alcohol Use Disorder. <i>Cell Reports</i> , 2020, 33, 108238.	2.9	87
312	In replyâ€“Pharmacotherapies for Alcohol Use Disorder: Over Both Sides of the Atlantic Ocean. <i>Mayo Clinic Proceedings</i> , 2020, 95, 2295-2296.	1.4	0
313	Molecular mechanisms of psychiatric diseases. <i>Neurobiology of Disease</i> , 2020, 146, 105136.	2.1	21
314	Geographic Differences in Receipt of Addictions Treatment in a National Sample of Patients with Alcohol use Disorders from the U.S. Veterans Health Administration. <i>Substance Abuse</i> , 2021, 42, 559-568.	1.1	10
315	Correlates of alcohol use disorder pharmacotherapy receipt in medically insured patients. <i>Drug and Alcohol Dependence</i> , 2020, 214, 108174.	1.6	13
316	Improving translation of animal models of addiction and relapse by reverse translation. <i>Nature Reviews Neuroscience</i> , 2020, 21, 625-643.	4.9	117
317	Efficacy and safety of topiramate in binge eating disorder: a systematic review and meta-analysis. <i>CNS Spectrums</i> , 2021, 26, 459-467.	0.7	18
318	The Mesolimbic Dopamine Activity Signatures of Relapse to Alcohol-Seeking. <i>Journal of Neuroscience</i> , 2020, 40, 6409-6427.	1.7	49
320	Practice facilitation to implement alcohol-related care in Veterans Health Administration liver clinics: a study protocol. <i>Implementation Science Communications</i> , 2020, 1, 68.	0.8	7
321	Nicotine increases alcohol selfâ€“administration in male rats via a Î¼-opioid mechanism within the mesolimbic pathway. <i>British Journal of Pharmacology</i> , 2020, 177, 4516-4531.	2.7	9
322	Allosteric modulation of metabotropic glutamate receptors in alcohol use disorder: Insights from preclinical investigations. <i>Advances in Pharmacology</i> , 2020, 88, 193-232.	1.2	11

#	ARTICLE	IF	CITATIONS
323	Rates of Prescription Orders for United States Active Duty Service Members Diagnosed with Alcohol use Disorder. <i>Substance Abuse</i> , 2021, 42, 638-645.	1.1	0
324	Predictors of Opioid and Alcohol Pharmacotherapy Initiation at Hospital Discharge Among Patients Seen by an Inpatient Addiction Consult Service. <i>Journal of Addiction Medicine</i> , 2020, 14, 415-422.	1.4	39
325	Management of Sedation and Analgesia in Critically Ill Patients Receiving Long-Acting Naltrexone Therapy for Opioid Use Disorder. <i>Annals of the American Thoracic Society</i> , 2020, 17, 1352-1357.	1.5	6
326	Integrated stepped alcohol treatment for patients with HIV and at-risk alcohol use: a randomized trial. <i>Addiction Science &amp; Clinical Practice</i> , 2020, 15, 28.	1.2	11
327	SLC Neurotransmitter Transporters as Therapeutic Targets for Alcohol Use Disorder: A Narrative Review. <i>Alcoholism: Clinical and Experimental Research</i> , 2020, 44, 1965-1976.	1.4	6
328	Pharmacotherapies and personalized medicine for alcohol use disorder: a review. <i>Pharmacogenomics</i> , 2020, 21, 1117-1138.	0.6	11
329	Oxidative Stress and Neuroinflammation as a Pivot in Drug Abuse. A Focus on the Therapeutic Potential of Antioxidant and Anti-Inflammatory Agents and Biomolecules. <i>Antioxidants</i> , 2020, 9, 830.	2.2	40
330	Alcohol Addiction, Gut Microbiota, and Alcoholism Treatment: A Review. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6413.	1.8	71
331	Combined Pharmacotherapy and Cognitive Behavioral Therapy for Adults With Alcohol or Substance Use Disorders. <i>JAMA Network Open</i> , 2020, 3, e208279.	2.8	105
332	Prevention of Stroke by Modification of Additional Vascular and Lifestyle Risk Factors. , 2020, , 308-336.		0
333	Neural Mechanisms Underlying the Rewarding and Therapeutic Effects of Ketamine as a Treatment for Alcohol Use Disorder. <i>Frontiers in Behavioral Neuroscience</i> , 2020, 14, 593860.	1.0	10
334	Genomics and addiction treatment: The wave of the future. <i>Alcoholism &amp; Drug Abuse Weekly</i> , 2020, 32, 1-5.	0.0	0
335	National outpatient medication utilization for opioid and alcohol use disorders from 2014 to 2016. <i>Journal of Substance Abuse Treatment</i> , 2020, 119, 108141.	1.5	3
336	Effects of Alcohol Cue Reactivity on Subsequent Treatment Outcomes Among Treatment-Seeking Individuals with Alcohol Use Disorder: A Multisite Randomized, Double-blind, Placebo-Controlled Clinical Trial of Varenicline. <i>Alcoholism: Clinical and Experimental Research</i> , 2020, 44, 1431-1443.	1.4	23
337	Inpatient adoption of medications for alcohol use disorder: A mixed-methods formative evaluation involving key stakeholders. <i>Drug and Alcohol Dependence</i> , 2020, 213, 108090.	1.6	8
338	Clinical Utility of Routine Alcohol Screening in Large Health Care Systems for Addressing a Leading Epidemic in the US. <i>JAMA Network Open</i> , 2020, 3, e204757.	2.8	0
339	Occupancy of the kappa opioid receptor by naltrexone predicts reduction in drinking and craving. <i>Molecular Psychiatry</i> , 2021, 26, 5053-5060.	4.1	17
340	Treating Alcohol Use Disorder in Chronic Liver Disease. <i>Clinical Liver Disease</i> , 2020, 15, 77-80.	1.0	3

#	ARTICLE	IF	CITATIONS
341	Differential sensitivity of human neurons carrying $\mu$ 4 opioid receptor (MOR) N40D variants in response to ethanol. <i>Alcohol</i> , 2020, 87, 97-109.	0.8	12
342	Effectiveness of naltrexone treatment for alcohol use disorders in HIV: a systematic review. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2020, 15, 24.	1.0	10
343	Lifestyle and Risk Factor Modification for Reduction of Atrial Fibrillation: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2020, 141, e750-e772.	1.6	237
344	OPRM1 Moderates Daily Associations of Naltrexone Adherence With Alcohol Consumption: Preliminary Evidence From a Mobile Health Trial. <i>Alcoholism: Clinical and Experimental Research</i> , 2020, 44, 983-991.	1.4	5
345	Effects of naltrexone on alcohol, sucrose, and saccharin binge-like drinking in C57BL/6J mice: a study with a multiple bottle choice procedure. <i>Behavioural Pharmacology</i> , 2020, 31, 256-271.	0.8	8
346	The ventral pallidum and relapse in alcohol seeking. <i>British Journal of Pharmacology</i> , 2020, 177, 3855-3864.	2.7	11
347	Assessment of the completeness of intervention reporting of randomized clinical trials for alcohol use disorders: Effect of the TIDieR checklist and guide. <i>Drug and Alcohol Dependence</i> , 2020, 208, 107824.	1.6	10
348	Complementary Roles for Ventral Pallidum Cell Types and Their Projections in Relapse. <i>Journal of Neuroscience</i> , 2020, 40, 880-893.	1.7	42
349	Mesenchymal stem cells as new perspective for the treatment of alcohol use disorder. <i>Gene Therapy</i> , 2020, 27, 471-473.	2.3	1
350	Brief Training on Medication-Assisted Treatment Improves Community Mental Health Clinicians'™ Confidence and Readiness to Address Substance Use Disorders. <i>Community Mental Health Journal</i> , 2020, 56, 1429-1435.	1.1	5
351	Documented brief intervention associated with reduced linkage to specialty addictions treatment in a national sample of VA patients with unhealthy alcohol use with and without alcohol use disorders. <i>Addiction</i> , 2020, 115, 668-678.	1.7	24
352	Outcomes of two quality improvement implementation interventions for depression services in adults with substance use problems. <i>American Journal of Drug and Alcohol Abuse</i> , 2020, 46, 251-261.	1.1	2
354	Differential sensitivity of alcohol drinking and partner preference to a CRFR1 antagonist in prairie voles and mice. <i>Hormones and Behavior</i> , 2020, 120, 104676.	1.0	2
355	Systematic review and meta-analysis of the moderating effect of rs1799971 in <i>OPRM1</i> , the $\mu$ 4 opioid receptor gene, on response to naltrexone treatment of alcohol use disorder. <i>Addiction</i> , 2020, 115, 1426-1437.	1.7	27
356	Executive function moderates naltrexone effects on methamphetamine-induced craving and subjective responses. <i>American Journal of Drug and Alcohol Abuse</i> , 2020, 46, 565-576.	1.1	8
357	Impact of Pharmacological Treatments for Opioid Use Disorder on Mortality. <i>CNS Drugs</i> , 2020, 34, 629-642.	2.7	7
358	Potential of Glial Cell Modulators in the Management of Substance Use Disorders. <i>CNS Drugs</i> , 2020, 34, 697-722.	2.7	9
359	The future of translational research on alcohol use disorder. <i>Addiction Biology</i> , 2021, 26, e12903.	1.4	22

#	ARTICLE	IF	CITATIONS
360	Assessing effects of oxytocin on alcohol consumption in socially housed prairie voles using radio frequency tracking. <i>Addiction Biology</i> , 2021, 26, e12893.	1.4	13
361	Is R(+)-Baclofen the best option for the future of Baclofen in alcohol dependence pharmacotherapy? Insights from the preclinical side. <i>Addiction Biology</i> , 2021, 26, e12892.	1.4	8
362	Polysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration. <i>Addiction</i> , 2021, 116, 96-104.	1.7	65
364	Do behavioral pharmacology findings predict clinical trial outcomes? A proof-of-concept in medication development for alcohol use disorder. <i>Neuropsychopharmacology</i> , 2021, 46, 519-527.	2.8	11
365	Cost-effectiveness of alcohol use treatments in patients with alcohol-related cirrhosis. <i>Journal of Hepatology</i> , 2021, 74, 1286-1294.	1.8	22
366	Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development. <i>Pharmacological Reviews</i> , 2021, 73, 163-201.	7.1	161
367	Mystical-type experiences occasioned by ketamine mediate its impact on at-risk drinking: Results from a randomized, controlled trial. <i>Journal of Psychopharmacology</i> , 2021, 35, 150-158.	2.0	38
368	A Population Pharmacokinetic Analysis of PF-5190457, a Novel Ghrelin Receptor Inverse Agonist in Healthy Volunteers and in Heavy Alcohol Drinkers. <i>Clinical Pharmacokinetics</i> , 2021, 60, 471-484.	1.6	7
369	Efficacy of N-acetylcysteine in the prevention of alcohol relapse-like drinking: Study in long-term ethanol-experienced male rats. <i>Journal of Neuroscience Research</i> , 2021, 99, 638-648.	1.3	7
370	Developing AHRQ's Feasibility Assessment Criteria for Wide-Scale Implementation of Patient-Centered Outcomes Research Findings. <i>Journal of General Internal Medicine</i> , 2021, 36, 374-382.	1.3	6
371	Multiple Psychiatric Morbidity and Continued Use of Naltrexone for Alcohol Use Disorder. <i>American Journal on Addictions</i> , 2021, 30, 55-64.	1.3	2
372	The pharmacological understandings of alcohol use and misuse. , 2021, , 107-140.		0
373	Organizational Capacity and Readiness to Provide Medication for Individuals with Co-Occurring Alcohol Use Disorders in Public Mental Health Settings. <i>Administration and Policy in Mental Health and Mental Health Services Research</i> , 2021, 48, 707-717.	1.2	6
374	The Role of the Family in Alcohol Use Disorder Recovery for Adults. <i>Alcohol Research: Current Reviews</i> , 2021, 41, 06.	1.9	26
375	Real-world effectiveness of pharmacological treatments of alcohol use disorders in a Swedish nationwide cohort of 125,556 patients. <i>Addiction</i> , 2021, 116, 1990-1998.	1.7	16
376	Pharmacotherapy of Alcohol Dependence: Treatment Readiness and Compliance Barriers. , 2021, , 1-12.		0
377	Substance Abuse and Coagulopathy. , 2021, , 387-395.		1
378	Metabolomics: small molecules that matter more. <i>Molecular Omics</i> , 2021, 17, 210-229.	1.4	68

#	ARTICLE	IF	CITATIONS
379	Alcohol Use Disorder: The Role of Medication in Recovery. <i>Alcohol Research: Current Reviews</i> , 2021, 41, 07.	1.9	24
380	Neuroendocrine Response to Exogenous Ghrelin Administration, Combined With Alcohol, in Heavy-Drinking Individuals: Findings From a Randomized, Double-Blind, Placebo-Controlled Human Laboratory Study. <i>International Journal of Neuropsychopharmacology</i> , 2021, 24, 464-476.	1.0	11
381	Addiction as a brain disease revised: why it still matters, and the need for consilience. <i>Neuropsychopharmacology</i> , 2021, 46, 1715-1723.	2.8	103
382	Dopamine and relapse to drug seeking. <i>Journal of Neurochemistry</i> , 2021, 157, 1572-1584.	2.1	8
383	Effect of Cognitive Bias Modification on Early Relapse Among Adults Undergoing Inpatient Alcohol Withdrawal Treatment. <i>JAMA Psychiatry</i> , 2021, 78, 133.	6.0	65
384	Use of Topiramate in the Spectrum of Addictive and Eating Disorders: A Systematic Review Comparing Treatment Schemes, Efficacy, and Safety Features. <i>CNS Drugs</i> , 2021, 35, 177-213.	2.7	11
386	Carnitine in Alcohol Use Disorders: A Scoping Review. <i>Alcoholism: Clinical and Experimental Research</i> , 2021, 45, 666-674.	1.4	6
387	Quality of Buprenorphine Care for Insured Adults With Opioid Use Disorder. <i>Medical Care</i> , 2021, 59, 393-401.	1.1	5
388	Accumbens coordinated reset stimulation in mice exhibits ameliorating aftereffects on binge alcohol drinking. <i>Brain Stimulation</i> , 2021, 14, 330-334.	0.7	9
389	New approved and emerging pharmacological approaches to alcohol use disorder: a review of clinical studies. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1291-1303.	0.9	18
390	Reward drinking and naltrexone treatment response among young adult heavy drinkers. <i>Addiction</i> , 2021, 116, 2360-2371.	1.7	13
391	fMRI-based prediction of naltrexone response in alcohol use disorder: a replication study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2021, 271, 915-927.	1.8	11
392	Evaluation of spin in the abstracts of systematic reviews and meta-analyses focused on treatments of alcohol use disorder. <i>American Journal of Drug and Alcohol Abuse</i> , 2021, 47, 476-485.	1.1	1
393	Nalmefene attenuates neural alcohol cue-reactivity in the ventral striatum and subjective alcohol craving in patients with alcohol use disorder. <i>Psychopharmacology</i> , 2021, 238, 2179-2189.	1.5	14
395	Neurobiology of alcohol seeking behavior. <i>Journal of Neurochemistry</i> , 2021, 157, 1585-1614.	2.1	29
396	Naltrexone Initiation in the Inpatient Setting for Alcohol Use Disorder: A Systematic Review of Clinical Outcomes. <i>Mayo Clinic Proceedings Innovations, Quality &amp; Outcomes</i> , 2021, 5, 495-501.	1.2	9
397	Commentary on Donoghue: Low prescribing rates of pharmacotherapy for alcohol use disorder limit potential public health impact. <i>Addiction</i> , 2021, 116, 3027-3028.	1.7	4
398	Anticraving medication for moderate to severe alcohol use disorder. <i>Cmaj</i> , 2021, 193, E695-E695.	0.9	1

#	ARTICLE	IF	CITATIONS
399	The correlates and extent of prescribing of medications for alcohol relapse prevention in England. <i>Addiction</i> , 2021, 116, 3019-3026.	1.7	7
400	A cascade of care for alcohol use disorder: Using 2015–2019 National Survey on Drug Use and Health data to identify gaps in past 12-month care. <i>Alcoholism: Clinical and Experimental Research</i> , 2021, 45, 1276-1286.	1.4	28
401	Medications to Treat Alcohol Use Disorder: Targeting the Dark Side. <i>American Journal of Psychiatry</i> , 2021, 178, 375-377.	4.0	2
402	Reinforcing properties of alcohol in rats: Progressive ratio licking performance reinforced with 66% alcohol. <i>Physiology and Behavior</i> , 2021, 235, 113393.	1.0	1
403	Modernizing Withdrawal Management Services. <i>Canadian Journal of Addiction</i> , 2021, 12, 33-38.	0.2	0
404	Effect of extended-release naltrexone on alcohol consumption: a systematic review and meta-analysis. <i>Addiction</i> , 2022, 117, 271-281.	1.7	20
405	Efficacy and tolerability of baclofen in a U.S. community population with alcohol use disorder: a dose-response, randomized, controlled trial. <i>Neuropsychopharmacology</i> , 2021, 46, 2250-2256.	2.8	40
407	Receipt of evidence-based alcohol-related care in a national sample of transgender patients with unhealthy alcohol use: Overall and relative to non-transgender patients. <i>Journal of Substance Abuse Treatment</i> , 2021, 131, 108565.	1.5	3
408	Genetic contributions to alcohol use disorder treatment outcomes: a genome-wide pharmacogenomics study. <i>Neuropsychopharmacology</i> , 2021, 46, 2132-2139.	2.8	19
410	Diagnosis and Treatment of Alcohol-Associated Liver Disease. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 165.	3.8	144
411	Trends in the Use of Naltrexone for Addiction Treatment among Alcohol Use Disorder Admissions in U.S. Substance Use Treatment Facilities. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 8884.	1.2	5
412	Practical Assessment of Alcohol Use Disorder in Routine Primary Care: Performance of an Alcohol Symptom Checklist. <i>Journal of General Internal Medicine</i> , 2022, 37, 1885-1893.	1.3	15
413	Epigenetic moderators of naltrexone efficacy in reducing heavy drinking in Alcohol Use Disorder: a randomized trial. <i>Pharmacogenomics Journal</i> , 2022, 22, 1-8.	0.9	2
414	Clinical management of the alcohol withdrawal syndrome. <i>Addiction</i> , 2022, 117, 804-814.	1.7	22
415	Unhealthy alcohol use in a 65-year-old man awaiting surgery. <i>Cmaj</i> , 2021, 193, E1250-E1252.	0.9	1
416	Approaching Alcohol Use Disorder After Liver Transplantation for Acute Alcoholic Hepatitis. <i>Clinics in Liver Disease</i> , 2021, 25, 645-671.	1.0	4
418	Understanding low treatment seeking rates for alcohol use disorder: A narrative review of the literature and opportunities for improvement. <i>American Journal of Drug and Alcohol Abuse</i> , 2021, 47, 664-679.	1.1	16
419	Baseline severity and the prediction of placebo response in clinical trials for alcohol dependence: A meta-regression analysis to develop an enrichment strategy. <i>Alcoholism: Clinical and Experimental Research</i> , 2021, 45, 1722-1734.	1.4	12

#	ARTICLE	IF	CITATIONS
420	Non-invasive and invasive brain stimulation in alcohol use disorders: A critical review of selected human evidence and methodological considerations to guide future research. <i>Comprehensive Psychiatry</i> , 2021, 109, 152257.	1.5	5
422	Increased network centrality of the anterior insula in early abstinence from alcohol. <i>Addiction Biology</i> , 2022, 27, e13096.	1.4	14
423	Alcoholic Hepatitis. <i>Clinical Liver Disease</i> , 2021, 18, 90-95.	1.0	6
424	Association between dynamic dose increases of buprenorphine for treatment of opioid use disorder and risk of relapse. <i>Addiction</i> , 2022, 117, 637-645.	1.7	4
425	Characterizing Substance Use Disorders among Transgender Adults Receiving Care at a Large Urban Safety Net Hospital. <i>Journal of Addiction Medicine</i> , 2021, Publish Ahead of Print, .	1.4	2
426	An examination between treatment type and treatment retention in persons with opioid and co-occurring alcohol use disorders. <i>Drug and Alcohol Dependence</i> , 2021, 226, 108886.	1.6	8
427	Use of pharmacotherapy for alcohol use disorder in Manitoba, Canada: A whole-population cohort study. <i>PLoS ONE</i> , 2021, 16, e0257025.	1.1	6
428	First-line Medications for the Outpatient Treatment of Alcohol Use Disorder: A Systematic Review of Perceived Barriers. <i>Journal of Addiction Medicine</i> , 2022, 16, e210-e218.	1.4	4
429	Alcohol and drug offenses and suicide risk among men who purchased a handgun in California: A cohort study. <i>Preventive Medicine</i> , 2021, 153, 106821.	1.6	3
430	Alterations of kynurenine pathway in alcohol use disorder and abstinence: a link with gut microbiota, peripheral inflammation and psychological symptoms. <i>Translational Psychiatry</i> , 2021, 11, 503.	2.4	32
431	Immune treatments for alcohol use disorder: A translational framework. <i>Brain, Behavior, and Immunity</i> , 2021, 97, 349-364.	2.0	30
432	Optimizing opioid use disorder treatment with naltrexone or buprenorphine. <i>Drug and Alcohol Dependence</i> , 2021, 228, 109031.	1.6	4
433	Mechanistic insights into the efficacy of memantine in treating certain drug addictions. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 111, 110409.	2.5	9
436	Characterizing the Variation of Alcohol Cessation Pharmacotherapy in Primary Care. <i>Journal of General Internal Medicine</i> , 2021, 36, 1989-1996.	1.3	5
437	The Human Laboratory and Drug Development in Alcohol Use Disorder: Recent Updates. <i>Methods in Molecular Biology</i> , 2019, 2011, 195-219.	0.4	5
438	Targeting the GABAB Receptor for the Treatment of Alcohol Use Disorder. , 2016, , 287-307.		6
439	Anticonvulsants to Treat Cannabis Use Disorder. , 2019, , 213-220.		1
440	Routine Assessment of Symptoms of Substance Use Disorders in Primary Care: Prevalence and Severity of Reported Symptoms. <i>Journal of General Internal Medicine</i> , 2020, 35, 1111-1119.	1.3	34



#	ARTICLE	IF	CITATIONS
441	Alkohol. , 2019, , 93-119.		1
442	Appointment wait-times and arrival for patients at a low-barrier access addiction clinic. <i>Journal of Substance Abuse Treatment</i> , 2020, 114, 108011.	1.5	36
443	Evidence-Based Pharmacotherapies for Alcohol Use Disorder. <i>Mayo Clinic Proceedings</i> , 2020, 95, 1964-1977.	1.4	40
444	Tailored interventions to support the implementation of the German national guideline on screening, diagnosis and treatment of alcohol-related disorders: a project protocol. <i>Sucht</i> , 2019, 65, 373-381.	0.1	4
445	Changes in the elimination and resurgence of alcohol-maintained behavior in rats and the effects of naltrexone.. <i>Psychology of Addictive Behaviors</i> , 2020, 34, 10-22.	1.4	7
446	Effects of cannabidiol on alcohol-related outcomes: A review of preclinical and human research.. <i>Experimental and Clinical Psychopharmacology</i> , 2019, 27, 359-369.	1.3	24
447	Justice involvement and treatment use among rural veterans.. <i>Journal of Rural Mental Health</i> , 2018, 42, 46-59.	0.5	4
448	Treatment of alcohol use disorder: Integration of Alcoholics Anonymous and cognitive behavioral therapy.. <i>Training and Education in Professional Psychology</i> , 2020, 14, 19-26.	0.9	10
449	Animal models of alcohol use disorder and the brain: From casual drinking to dependence.. <i>Translational Issues in Psychological Science</i> , 2019, 5, 222-242.	0.6	13
450	Practice Habits, Knowledge, and Attitudes of Hepatologists to Alcohol Use Disorder Medication: Sobering Gaps and Opportunities. <i>Transplantation Direct</i> , 2020, 6, e603.	0.8	11
452	SFâ€œ6D utility scores for alcohol use disorder status and alcohol consumption risk levels in the US population. <i>Addiction</i> , 2021, 116, 1034-1042.	1.7	8
453	The Nucleus Accumbens: Mechanisms of Addiction across Drug Classes Reflect the Importance of Glutamate Homeostasis. <i>Pharmacological Reviews</i> , 2016, 68, 816-871.	7.1	442
454	Recent advances in alcoholic hepatitis. <i>F1000Research</i> , 2020, 9, 97.	0.8	12
455	Implementation of a Process for Initiating Naltrexone in Patients Hospitalized for Alcohol Detoxification or Withdrawal. <i>Journal of Hospital Medicine</i> , 2018, 13, 221-228.	0.7	51
456	Risks and Benefits of Nalmefene in the Treatment of Adult Alcohol Dependence: A Systematic Literature Review and Meta-Analysis of Published and Unpublished Double-Blind Randomized Controlled Trials. <i>PLoS Medicine</i> , 2015, 12, e1001924.	3.9	84
457	Drug therapy for alcohol dependence in primary care in the UK: A Clinical Practice Research Datalink study. <i>PLoS ONE</i> , 2017, 12, e0173272.	1.1	28
458	Harms associated with taking nalmefene for substance use and impulse control disorders: A systematic review and meta-analysis of randomised controlled trials. <i>PLoS ONE</i> , 2017, 12, e0183821.	1.1	10
459	Recognition of a disulfiram ethanol reaction in the emergency department is not always straightforward. <i>PLoS ONE</i> , 2020, 15, e0243222.	1.1	5

#	ARTICLE	IF	CITATIONS
460	Treatments for internet addiction, sex addiction and compulsive buying: A meta-analysis. Journal of Behavioral Addictions, 2020, 9, 14-43.	1.9	37
461	Alcohol Dependence and Harmful Use of Alcohol: Diagnosis and Treatment Options. Deutsches A&#x0308;rzteblatt International, 2016, 113, 301-10.	0.6	50
462	Alcohol Use Disorder and Antisocial and Borderline Personality Disorders. Alcohol Research: Current Reviews, 2019, 40, .	1.9	34
463	Alcoholic liver disease and hepatitis C virus infection. World Journal of Gastroenterology, 2016, 22, 1411.	1.4	41
464	Taurine, energy drinks, and neuroendocrine effects. Cleveland Clinic Journal of Medicine, 2016, 83, 895-904.	0.6	41
465	Prevention, early intervention, and harm reduction of substance use in adolescents. Indian Journal of Psychiatry, 2017, 59, 111.	0.4	33
466	Pharmacotherapy for relapse prevention of alcohol use disorder in the Indian setting: A systematic review. Industrial Psychiatry, 2018, 27, 163.	0.3	2
467	Treatment of the Alcohol Use Disorder at Outpatient Psychiatric Clinic. Journal of Korean Neuropsychiatric Association, 2019, 58, 159.	0.2	4
468	Practical outpatient pharmacotherapy for alcohol use disorder. Drugs in Context, 2018, 7, 1-14.	1.0	20
469	Reducing and preventing alcohol misuse and its consequences: A Grand Challenge for social work. The International Journal of Alcohol and Drug Research, 2016, 5, 73-83.	0.9	26
470	Use of Medications for the Treatment of Alcohol Dependence: A Retrospective Study Conducted in 2011-2012. Current Drug Research Reviews, 2021, 13, 154-164.	0.7	1
471	The impact of methamphetamine/amphetamine use on receipt and outcomes of medications for opioid use disorder: a systematic review. Addiction Science & Clinical Practice, 2021, 16, 62.	1.2	29
472	New Australian guidelines for the treatment of alcohol problems: an overview of recommendations. Medical Journal of Australia, 2021, 215, S3-S32.	0.8	34
474	Clinical interventions for adults with comorbid alcohol use and depressive disorders: A systematic review and network meta-analysis. PLoS Medicine, 2021, 18, e1003822.	3.9	8
475	Care of the Alcoholic Patient. , 2015, , 1-18.		0
476	Medical Practice Variations in Mental Health and Addictions Care. , 2015, , 1-41.		2
477	Literaturverzeichnis zu Voderholzer, Hohagen (Hrsg.): Therapie psychischer Erkrankungen, 10. Auflage. , 2015, , e1-e96.		0
479	Pharmacological treatment options for alcohol use disorder. Dusunen Adam, 2015, , 283-300.	0.0	0

#	ARTICLE	IF	CITATIONS
480	10.ÂAlcohol Use. , 2016, , .		0
481	Diepe hersenstimulatie bij verslaving. , 2016, , 143-152.		0
482	Alcohol Use and Management. , 2016, , 151-159.		2
483	Literaturverzeichnis zu Voderholzer/Hohagen (Hrsg.): Therapie psychischer Erkrankungen, 13. Auflage. , 2017, , 1-111.		0
484	Opinion: Real-Time fMRI Neurofeedback and the Application of the Neuropeptide Oxytocin as Promising New Treatment Approaches in Internet Addiction?. Studies in Neuroscience, Psychology and Behavioral Economics, 2017, , 311-321.	0.1	2
485	Risk/Benefit Discussion of Alcohol Use Disorder Medications: Behavioral Economic Considerations and General Recommendations. Journal of Addiction Research & Therapy, 2017, 08, .	0.2	0
486	Alkohol. , 2017, , 1-28.		0
487	La terapia farmacologica dell'alcolismo: l'acamprosato e il nalmefene gli ultimi due farmaci anti-alcol approvati dagli organismi regolatori per la pratica clinica. Parte IV. Mission, 2017, , .	0.1	0
488	Alkohol. , 2018, , 609-629.		0
489	A Case Study of Two Alcoholic Liver Cirrhosis Patients. The Journal of Internal Korean Medicine, 2018, 39, 176-183.	0.0	3
490	Innovative pharmakologische Ansätze zur Behandlung von Suchterkrankungen. , 2019, , 81-90.		0
491	Alcohol Pharmacotherapy. , 2019, , 157-168.		0
492	Literaturverzeichnis zu Voderholzer/Hohagen (Hrsg.): Therapie psychischer Erkrankungen, 14. Auflage. , 2019, , 1-119.		0
495	Randomized Controlled Trials and the Efficacy of Psychotropic Medications. , 2020, , 1-56.		0
496	Alcoholic liver disease. Clinical example. Meditsinskiy Sovet, 2020, , 50-60.	0.1	2
497	Practice facilitation to promote evidence-based screening and management of unhealthy alcohol use in primary care: a practice-level randomized controlled trial. BMC Family Practice, 2020, 21, 93.	2.9	6
498	Is naltrexone an effective treatment for adults with alcohol use disorder?. Evidence-Based Practice, 2020, Publish Ahead of Print, .	0.0	0
499	Management of alcohol use disorder in patients with cirrhosis in the setting of liver transplantation. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 45-59.	8.2	50

#	ARTICLE	IF	CITATIONS
500	Reduced drinking and harm reduction in the treatment of alcohol use disorders. <i>Drugs and Alcohol Today</i> , 2021, 21, 31-44.	0.3	3
501	Effects of systemic glycine on accumbal glycine and dopamine levels and ethanol intake in male Wistar rats. <i>Journal of Neural Transmission</i> , 2021, 128, 83-94.	1.4	6
503	Care of the Alcoholic Patient. , 2020, , 1-18.		0
505	Pharmacotherapy of Alcohol Use Disorders. , 2020, , 1-17.		0
506	Alcohol and the Criminal Offender. , 2020, , 287-308.		0
508	Enfermedad hepática inducida por alcohol. <i>Medicine</i> , 2020, 13, 182-190.	0.0	1
510	Pharmacological Treatment of Alcohol Use Disorder. , 2021, , 123-139.		0
511	Neurobiology of Alcohol Dependence. , 2021, , 9-20.		1
512	Les addictions sous l'angle neurocognitif. <i>Psycho-oncologie</i> , 2020, 14, 80-86.	0.0	0
513	Role of Etiology Therapy in Management of Variceal Hemorrhage in Liver Cirrhosis. , 2021, , 41-51.		0
514	Adoption of injectable naltrexone in U.S. substance use disorder treatment programs. <i>Journal of Studies on Alcohol and Drugs</i> , 2015, 76, 143-51.	0.6	19
515	Medications for addiction treatment: an opportunity for prescribing clinicians to facilitate remission from alcohol and opioid use disorders. <i>Rhode Island Medical Journal (2013)</i> , 2014, 97, 20-4.	0.2	4
516	PURLs: Consider these medications to help patients stay sober. <i>Journal of Family Practice</i> , 2015, 64, 238-40.	0.2	0
517	Primary care management of alcohol use disorder and at-risk drinking: Part 2: counsel, prescribe, connect. <i>Canadian Family Physician</i> , 2015, 61, 515-21.	0.1	13
518	Nature and Treatment of Comorbid Alcohol Problems and Post Traumatic Stress Disorder Among American Military Personnel and Veterans. , 2016, 38, 133-40.		12
519	First-line medications for alcohol use disorders among public drug plan beneficiaries in Ontario. <i>Canadian Family Physician</i> , 2017, 63, e277-e283.	0.1	8
520	An Overview of Pharmacotherapy Options for Alcohol Use Disorder. <i>Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS</i> , 2018, 35, 48-58.	0.6	0
521	A Veteran With Alcohol Use Disorder and Acute Pancreatitis. <i>Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS</i> , 2018, 35, 34-39.	0.6	0

#	ARTICLE	IF	CITATIONS
522	Pharmacologic treatment of alcohol use disorder. <i>Canadian Family Physician</i> , 2020, 66, 583.	0.1	5
524	Participants' Treatment Perspectives on a Clinical Trial on the Use of Extended-Release Naltrexone for Substance Use Disorders: Considerations for Future Clinical Research. <i>Journal of Addiction Medicine</i> , 2021, 15, 390-395.	1.4	0
525	The Spectrum of Alcohol Use. <i>Medical Clinics of North America</i> , 2022, 106, 43-60.	1.1	10
526	Alcohol Use Disorder in Older Adults. <i>Clinics in Geriatric Medicine</i> , 2022, 38, 1-22.	1.0	11
527	Psilocybin targets a common molecular mechanism for cognitive impairment and increased craving in alcoholism. <i>Science Advances</i> , 2021, 7, eabh2399.	4.7	39
528	The STUN (STop UNhealthy) Alcohol Use Now trial: study protocol for an adaptive randomized trial on dissemination and implementation of screening and management of unhealthy alcohol use in primary care. <i>Trials</i> , 2021, 22, 810.	0.7	0
529	Treatment of alcohol use disorder in patients with liver disease. <i>Current Opinion in Pharmacology</i> , 2022, 62, 145-151.	1.7	6
530	Participants'™ Treatment Perspectives on a Clinical Trial on the Use of Extended-Release Naltrexone for Substance Use Disorders: Considerations for Future Clinical Research. <i>Journal of Addiction Medicine</i> , 2021, 15, 390-395.	1.4	2
531	Naltrexone moderates the association of alcohol use and affect among adolescent drinkers in daily life. <i>Alcoholism: Clinical and Experimental Research</i> , 2022, 46, 326-337.	1.4	2
532	Care of the Alcoholic Patient. , 2022, , 807-823.		0
533	Disrupted circadian expression of $\beta$ -arrestin 2 affects reward-related $\mu$ -opioid receptor function in alcohol dependence. <i>Journal of Neurochemistry</i> , 2022, 160, 454-468.	2.1	5
534	Patient-centered primary care and receipt of evidence-based alcohol-related care in the national Veterans Health Administration. <i>Journal of Substance Abuse Treatment</i> , 2022, 138, 108709.	1.5	2
535	The rates and measurement of adherence to acamprosate in randomised controlled clinical trials: A systematic review. <i>PLoS ONE</i> , 2022, 17, e0263350.	1.1	1
536	Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder. <i>Drugs</i> , 2022, 82, 251-274.	4.9	56
537	Repetitive Transcranial Magnetic Stimulation in Alcohol Dependence: A Randomized, Double-Blind, Sham-Controlled Proof-of-Concept Trial Targeting the Medial Prefrontal and Anterior Cingulate Cortices. <i>Biological Psychiatry</i> , 2022, 91, 1061-1069.	0.7	48
538	Management of psychiatric disorders in patients with hepatic and gastrointestinal diseases. <i>Indian Journal of Psychiatry</i> , 2022, 64, 379.	0.4	3
539	Practical assessment of DSM-5 alcohol use disorder criteria in routine care: High test-retest reliability of an Alcohol Symptom Checklist. <i>Alcoholism: Clinical and Experimental Research</i> , 2022, 46, 458-467.	1.4	12
540	Using practice facilitation to improve alcohol-related care in primary care: a mixed-methods pilot study protocol. <i>Addiction Science &amp; Clinical Practice</i> , 2022, 17, 19.	1.2	0

#	ARTICLE	IF	CITATIONS
541	A Meta-Regression of Trial Features Predicting the Effects of Alcohol Use Disorder Pharmacotherapies on Drinking Outcomes in Randomized Clinical Trials: A Secondary Data Analysis. <i>Alcohol and Alcoholism</i> , 2022, , .	0.9	1
542	Treating Alcohol Use Disorder in Patients with Alcohol-Associated Liver Disease: Controversies in Pharmacological Therapy. <i>Seminars in Liver Disease</i> , 2022, 42, 138-150.	1.8	9
543	From a systems view to spotting a hidden island: A narrative review implicating insula function in alcoholism. <i>Neuropharmacology</i> , 2022, 209, 108989.	2.0	14
544	P.0310 Validation of neural biomarkers for predicting naltrexone response in patients with alcohol dependence: a longitudinal functional magnetic resonance imaging study. <i>European Neuropsychopharmacology</i> , 2021, 53, S225.	0.3	0
545	Alcohol use disorder in community management of chronic liver diseases. <i>Hepatology</i> , 2023, 77, 1006-1021.	3.6	13
546	Management of Alcohol Use Disorder in Patients With Alcoholic Liver Disease. <i>Journal of Clinical and Experimental Hepatology</i> , 2022, 12, 1514-1526.	0.4	4
549	New pharmacological targets for the treatment of excessive alcohol use. <i>Current Drug Research Reviews</i> , 2022, 14, .	0.7	0
550	Psychosocial and medication interventions to stop or reduce alcohol consumption during pregnancy. <i>The Cochrane Library</i> , 2022, 2022, .	1.5	0
551	Incidence and Progression of Alcohol-Associated Liver Disease After Medical Therapy for Alcohol Use Disorder. <i>JAMA Network Open</i> , 2022, 5, e2213014.	2.8	36
552	The Need for Integrating Addiction Medicine and Hepatology. <i>JAMA Network Open</i> , 2022, 5, e2213022.	2.8	4
555	Efficacy of Extended-Release Injectable Naltrexone on Alcohol Use Disorder Treatment: A Systematic Review. <i>Journal of Psychoactive Drugs</i> , 2023, 55, 233-245.	1.0	0
556	Perspectives on the pharmacological management of alcohol use disorder: Are the approved medications effective?. <i>European Journal of Internal Medicine</i> , 2022, , .	1.0	4
557	An ethical analysis of endoscopic therapy decision-making in patients with refractory substance use disorder and chronic pancreatitis. <i>Pancreatology</i> , 2022, , .	0.5	0
558	Pharmacotherapies for Adults With Alcohol Use Disorders: A Systematic Review and Network Meta-analysis. <i>Journal of Addiction Medicine</i> , 2022, 16, 630-638.	1.4	12
559	Barriers and Facilitators to Changing Drinking and Receiving Alcohol-Related Care: Interviews with Veterans Health Administration Primary Care Patients who Indicated Interest but Did Not Enroll in An Alcohol Care Management Intervention Trial. <i>Substance Abuse</i> , 2022, 43, 1197-1206.	1.1	4
560	Medication prescribing for alcohol use disorders during alcohol-related encounters in a Colorado regional healthcare system. <i>Alcoholism: Clinical and Experimental Research</i> , 2022, 46, 1094-1102.	1.4	1
561	Therapeutic drug monitoring in relapse prevention of alcohol dependent patients. <i>Pharmacopsychiatry</i> , 2022, , .	1.7	0
562	Alcohol use in the year following approach bias modification during inpatient withdrawal: secondary outcomes from a double-blind, multi-site randomized controlled trial. <i>Addiction</i> , 2022, 117, 2837-2846.	1.7	14

#	ARTICLE	IF	CITATIONS
563	Association of topiramate prescribed for any indication with reduced alcohol consumption in electronic health record data. <i>Addiction</i> , 2022, 117, 2826-2836.	1.7	1
564	Efficacy of ketamine intervention to decrease alcohol use, cravings, and withdrawal symptoms in adults with problematic alcohol use or alcohol use disorder: A systematic review and comprehensive analysis of mechanism of actions.. <i>Drug and Alcohol Dependence</i> , 2022, 239, 109606.	1.6	13
565	An Alcohol Symptom Checklist identifies high rates of alcohol use disorder in primary care patients who screen positive for depression and high-risk drinking. <i>BMC Health Services Research</i> , 2022, 22, .	0.9	2
566	The Added Value of Pharmacotherapy to Cognitive Behavior Therapy And Vice Versa in the Treatment of Alcohol Use Disorders: A Systematic Review. <i>Alcohol and Alcoholism</i> , 0, , .	0.9	2
567	NEUROSCIENTIFIC BASIS OF TREATMENT FOR SUBSTANCE USE DISORDERS. <i>Noropsikiyatri Arsivi</i> , 2022, , .	0.2	0
568	Targeting prefrontal cortex GABAergic microcircuits for the treatment of alcohol use disorder. <i>Frontiers in Synaptic Neuroscience</i> , 0, 14, .	1.3	12
571	Off-label and investigational drugs in the treatment of alcohol use disorder: A critical review. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	9
572	Evidence-Based Practices for Co-occurring Addiction and Mental Illness. , 2022, , 331-349.		0
573	Thiol-Disulfide Homeostasis as an Oxidative Stress Indicator. <i>Biomarkers in Disease</i> , 2022, , 801-818.	0.0	1
574	Looking Back, Looking Forward: Current Medications and Innovative Potential Medications to Treat Alcohol Use Disorder. <i>Alcohol Research: Current Reviews</i> , 2022, 42, .	1.9	5
575	Extended-Release Naltrexone and Case Management for Treatment of Alcohol Use Disorder in the Emergency Department. <i>Annals of Emergency Medicine</i> , 2023, 81, 440-449.	0.3	7
577	Targeted Oral Naltrexone for Mild to Moderate Alcohol Use Disorder Among Sexual and Gender Minority Men: A Randomized Trial. <i>American Journal of Psychiatry</i> , 2022, 179, 915-926.	4.0	8
578	Alcohol consumption, alcohol use disorder and organ transplantation. <i>Minerva Gastroenterology</i> , 2024, 69, .	0.3	2
579	Topiramate, Naltrexone, and Acamprosate in the Treatment of Alcohol Use Disorders. , 2022, , 2535-2550.		0
580	Randomized Controlled Trials and the Efficacy of Psychotropic Medications. , 2022, , 305-359.		0
581	Pharmacotherapy of Alcohol Dependence: Treatment Readiness and Compliance Barriers. , 2022, , 4497-4507.		0
582	Pharmacotherapy of Alcohol Use Disorders. , 2022, , 4303-4319.		0
583	Feasibility, Acceptability, and Preliminary Outcomes of an Integrated Telemedicine Intervention Combining Naltrexone and Cognitive Behavioral Therapy for Alcohol Use Disorder. <i>Telemedicine Reports</i> , 2022, 3, 184-190.	0.5	1

#	ARTICLE	IF	CITATIONS
584	Relationship Between Primary Care Providers'™ Perceptions of Alcohol Use Disorder And Pharmacotherapy Prescribing Rates. <i>Alcohol and Alcoholism</i> , 0, , .	0.9	0
585	Effectiveness of a pharmacist-delivered primary care telemedicine intervention to increase access to pharmacotherapy and specialty treatment for alcohol use problems: Protocol for the alcohol telemedicine consult cluster-randomized pragmatic trial. <i>Contemporary Clinical Trials</i> , 2022, 123, 107004.	0.8	0
586	Comparisons of psychological distress and self-stigma among three types of substance use disorders receiving treatment-as-usual approaches: real-world data from a 9-month longitudinal study. <i>Therapeutic Advances in Chronic Disease</i> , 2022, 13, 204062232211403.	1.1	9
587	Behandlung von riskantem, schädlichem und abhängigem Alkoholgebrauch. , 2022, , 51-356.		0
588	Hazardous drinking and alcohol use disorders. <i>Nature Reviews Disease Primers</i> , 2022, 8, .	18.1	24
590	Liver transplantation for alcohol-associated hepatitis. <i>Current Opinion in Organ Transplantation</i> , 2023, 28, 85-94.	0.8	1
591	The life and times of endogenous opioid peptides: Updated understanding of synthesis, spatiotemporal dynamics, and the clinical impact in alcohol use disorder. <i>Neuropharmacology</i> , 2023, 225, 109376.	2.0	1
592	Effects of baclofen on insular gain anticipation in alcohol-dependent patients – a randomized, placebo-controlled, pharmacofMRI pilot trial. <i>Psychopharmacology</i> , 2023, 240, 171-183.	1.5	0
593	Extended-release naltrexone for people with alcohol use disorder on therapeutic anticoagulation: A case series. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2022, 47, 2393-2396.	0.7	1
594	Therapeutic Pipeline in Alcohol-Associated Liver Disease. <i>Seminars in Liver Disease</i> , 2023, 43, 060-076.	1.8	4
595	Insight into the role of the gut-brain axis in alcohol-related responses: Emphasis on GLP-1, amylin, and ghrelin. <i>Frontiers in Psychiatry</i> , 0, 13, .	1.3	4
596	Substance-Related and Addictive Disorders. , 2022, , .		0
597	Understanding Ohio X-Waivered Advanced Practice Registered Nurses'™ Rate of Naltrexone Prescription for Alcohol Use Disordered Patients. <i>Journal of the American Psychiatric Nurses Association</i> , 0, , 107839032211510.	0.4	0
598	Types of addiction. , 2023, , 233-263.		0
599	Time to Treat Alcohol Use Disorder in the Emergency Department. <i>Annals of Emergency Medicine</i> , 2023, 81, 450-452.	0.3	2
600	Integrating Alcohol-Related Prevention and Treatment Into Primary Care. <i>JAMA Internal Medicine</i> , 2023, 183, 319.	2.6	12
601	Study protocol for a factorial-randomized controlled trial evaluating the implementation, costs, effectiveness, and sustainment of digital therapeutics for substance use disorder in primary care (DIGITS Trial). <i>Implementation Science</i> , 2023, 18, .	2.5	2
602	Alcohol treatment discussions and clinical outcomes among patients with alcohol-related cirrhosis. <i>BMC Gastroenterology</i> , 2023, 23, .	0.8	4



#	ARTICLE	IF	CITATIONS
603	The impact of COVID-19 on trends in alcohol use disorder treatment in Veterans Health Administration. <i>Addiction</i> , 2023, 118, 1062-1071.	1.7	2
604	Liver transplantation in alcohol-associated liver disease: ensuring equity through new processes. <i>Liver Transplantation</i> , 2023, 29, 539-547.	1.3	1
605	The management of alcohol use disorder in the emergency department, is it time for version 2.0?. <i>Canadian Journal of Emergency Medicine</i> , 2023, 25, 108-109.	0.5	0
606	Causes and Treatments of Alcohol Addiction among Adolescents. , 0, 8, 1899-1905.		0
607	Deep brain stimulation of the nucleus accumbens in treatment-resistant alcohol use disorder: a double-blind randomized controlled multi-center trial. <i>Translational Psychiatry</i> , 2023, 13, .	2.4	10
608	The role of nicotinic receptors in alcohol consumption. <i>Pharmacological Research</i> , 2023, 190, 106705.	3.1	1
609	Effects of topiramate therapy on serum bicarbonate concentration in a sample of 10,279 veterans. <i>Alcoholism: Clinical and Experimental Research</i> , 2023, 47, 438-447.	1.4	1
610	Which interventions for alcohol use should be included in a universal healthcare benefit package? An umbrella review of targeted interventions to address harmful drinking and dependence. <i>BMC Public Health</i> , 2023, 23, .	1.2	1
611	Association between clinical measures of unhealthy alcohol use and subsequent year hospital admissions in a primary care population. <i>Drug and Alcohol Dependence</i> , 2023, 245, 109821.	1.6	1
612	Sex-related differences in the efficacy of Baclofen enantiomers on self-administered alcohol in a binge drinking pattern and dopamine release in the core of the nucleus accumbens. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	0
613	Consuming oral cannabidiol prior to a standard alcohol dose has minimal effect on breath alcohol level and subjective effects of alcohol. <i>Psychopharmacology</i> , 2023, 240, 1119-1129.	1.5	0
614	Medications for alcohol use disorder improve survival in patients with hazardous drinking and alcohol-associated cirrhosis. <i>Hepatology Communications</i> , 2023, 7, .	2.0	12
615	Emergency Department Management of Patients With Alcohol Intoxication, Alcohol Withdrawal, and Alcohol Use Disorder: A White Paper Prepared for the American Academy of Emergency Medicine. <i>Journal of Emergency Medicine</i> , 2023, 64, 517-540.	0.3	7
616	Using naltrexone to validate a human laboratory test system to screen new medications for alcoholism (TESMA)- a randomized clinical trial. <i>Translational Psychiatry</i> , 2023, 13, .	2.4	1
617	Stress-related neuropeptide systems as targets for treatment of alcohol addiction: A clinical perspective. <i>Journal of Internal Medicine</i> , 2023, 293, 559-573.	2.7	2
618	Prevalence and incidence of alcohol dependence: cross-sectional primary care analysis in Liverpool, UK. <i>BMJ Open</i> , 2023, 13, e071024.	0.8	1
619	Pharmacotherapy options for alcohol use disorder in patients with alcohol-associated liver disease: a brief guide for clinicians. <i>Clinical Liver Disease</i> , 2023, 21, 125-129.	1.0	1
621	Drugs For Relapse Prevention in Addiction: Review of Psychological and Neurological Factors, Genetics and Neurobiological Mechanisms. <i>Frontiers in Clinical Drug Research CNS and Neurological Disorders</i> , 2023, , 158-237.	0.1	0

#	ARTICLE	IF	CITATIONS
629	Approach-Bias Retraining and Other Training Interventions as Add-On in the Treatment of AUD Patients. <i>Current Topics in Behavioral Neurosciences</i> , 2023, , .	0.8	6
633	Accelerating addiction research via Open Science and Team Science. <i>Psychology of Learning and Motivation - Advances in Research and Theory</i> , 2023, , .	0.5	0
637	Therapeutics for Substance-Using Women: The Need to Elucidate Sex-Specific Targets for Better-Tailored Treatments. <i>Handbook of Experimental Pharmacology</i> , 2023, , .	0.9	0
641	Pharmacological Treatment of Substance Use Disorders. , 2023, , 1-28.		0
647	Alcohol Use Disorder. , 2023, , .		0
653	Approved, Promising, and Experimental Medications for Treatment of Alcohol Use Disorder. , 2023, , 261-288.		0
654	The Clinical Benefits of Non-abstinent Outcomes in Alcohol Use Disorder Treatment: Evidence from Clinical Trials and Treatment Implications. , 2023, , 341-364.		0
657	GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders. <i>Nature Medicine</i> , 2023, 29, 2993-2995.	15.2	2
661	Treatments for Substance Use Disorders. , 2023, , .		0
670	PrÃ©vention et traitement des complications digestives de l'usage d'alcool. , 2023, , 487-497.		0
671	Traitement du mÃ©susage d'alcool. , 2023, , 609-622.		0
680	Alcohol-related liver disease. , 0, , 188-196.		0
683	Current treatments of alcohol use disorder. <i>International Review of Neurobiology</i> , 2024, , 127-152.	0.9	0
687	Repurposing drugs for treatment of alcohol use disorder. <i>International Review of Neurobiology</i> , 2024, , 153-185.	0.9	0